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ABSTRACT OF THESIS 
 
 
IMPACT OF ERGOT ALKALOID AND ESTRADIOL 17B ON WHOLE-BODY 
PROTEIN TURNOVER AND EXPRESSION OF MTOR PATHWAY PROTEINS IN 
MUSCLE OF CATTLE 
 
Beef cattle consuming endophyte infected tall fescue typically exhibit reduced 
performance in terms of both decreased dry matter intake (DMI) and growth rates. It has 
been suggested that lower concentrations of circulating IGF-1 (an important stimulator of 
the mTOR pathway and ultimately protein synthesis), as observed with consumption of 
ergot alkaloids, contribute to reduced growth rates. The objective of the current study was 
to determine if fescue-derived alkaloids decrease muscle protein synthesis though 
inhibitory action on the mTOR pathway via a direct effect on signal proteins, and if these 
negative effects can be alleviated by implantation with anabolic agents. Thirty-two 
Holstein steers were used in a 2x2 factorial design, and treatments consisted of 
intramuscular administration of bromocriptine (vehicle or 0.1 mg/kg BW) and a subdermal 
estradiol implant (with or without). Throughout the 35-day experiment, steers were fed a 
corn silage-based diet, with intake restricted to 1.5 times maintenance energy requirement. 
Bromocriptine injections were given every three days for 34 days. On days 27 through 32, 
steers were moved to metabolism stalls for urine collection and whole-body protein 
turnover was determined using a single pulse dose of [15N] glycine into the jugular vein on 
day 28. On day 35, muscle samples were collected from the musculus obliquus externus 
abdominis before (basal state) and 60 mins after (stimulated state) an i.v. glucose challenge 
(0.25 g glucose/kg). Blood samples were collected at regular intervals before and after 
glucose infusion for determination of circulating concentrations of glucose and insulin. 
Bromocriptine reduced insulin and glucose clearance following the glucose challenge, 
indicating decreased insulin sensitivity and possible disruption of glucose uptake and 
metabolism in the skeletal muscle. This suggests that fescue-derived alkaloids are 
detrimental to growing cattle in terms of overall glucose homeostasis and energy 
metabolism. Conversely, analysis of whole-body protein turnover demonstrated that 
bromocriptine does not appear to affect protein synthesis or N retention and western 
immunoblot analysis of skeletal muscle showed that it did not affect abundance of S6K1 
     
 
or 4E-BP1, so does not appear to inhibit activation of the mTOR pathway or protein 
synthesis. Implantation improved N retention, decreased protein turnover, and had no 
effect on protein synthesis, suggesting that steroidal implants promote protein accretion 
through unchanged rates of synthesis and decreased degradation, even in the presence of 
bromocriptine, resulting in improved daily gains. Implanted steers likely experienced 
increased IGF-1 signaling, but downstream activation of mTOR, S6K and 4E-BP1, and 
thus increased protein synthesis did not occur as expected. Overall, this data suggests that 
fescue derived alkaloids do not have a negative impact on muscle protein synthetic 
pathways, independent of DMI. 
 
 
KEYWORDS: ruminant, bovine, ergot alkaloids, mtor pathway, protein metabolism   
 
 
 
 
 
Taylor Dawn Ferguson 
(Name of Student) 
 
10/30/2020 
            Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMPACT OF ERGOT ALKALOID AND ESTRADIOL 17B ON WHOLE-BODY 
PROTEIN TURNOVER AND EXPRESSION OF MTOR PATHWAY PROTEINS IN 
MUSCLE OF CATTLE 
 
 
By 
Taylor Dawn Ferguson 
 
 
 
 
 
 
 
 
 
 
 
Dr. Kyle R. McLeod 
Director of Thesis 
 
Dr. David L. Harmon 
Director of Graduate Studies 
 
10/30/2020 
            Date 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGMENTS 
 I would like to thank my advisor, Dr. Kyle McLeod, for giving me this 
opportunity; I have appreciated his guidance, expertise, and patience through this long 
process. I also want to thank my committee members Dr. Kristine Urschel and Dr. Eric 
Vanzant for their time and guidance. Especially, Dr. Urschel for the use of her lab and 
assistance with western blotting, and Dr. Vanzant for all his help with my nemesis — 
statistics. Further thanks goes to Dr. James Matthews for letting me pick his brain about 
blotting on occasion.  
 I never would have managed my thesis work without the help of our lab 
technicians Adam Bohannon, Cynthia Roberts, and Winston Lin, who are always willing 
to answer questions and help when needed. Adam’s expertise in the lab and assistance 
with animal care was invaluable and I literally could not have completed my study 
without him. Additional thanks go to the University of Kentucky Beef Unit farm staff, 
especially Lauren Clark and Kirk Vanzant, for their assistance with day to day care of my 
animals and completion of my experiment. Thank you to Kyle McLean for assistance on 
biopsy day and Hannah Herzing for running ion exchange columns. 
 I have been lucky to have the support of many other people during my time at UK 
and have made invaluable friendships. I am grateful for the guidance of Amanda 
Pesqueira Schiff and the continued support I have received from Miriam Snider, Sophie 
Stratton, and Ashley Gerritsen — I never would have made it to this point without you 
guys. Special thanks go to Dr. Caroline Loos for teaching me the art of western blotting 
and for all her help troubleshooting when it invariably went wrong.  
iv 
 
 Lastly, I would like to thank my brother, Nathan, for always keeping me honest 
and being the only person in my family science-y enough to understand what this thesis is 
about, and his wife Kaitlyn who definitely doesn’t care about cows but listens to me talk 
about rumens nonetheless. Thank you to my ever supportive and long-suffering parents, 
Joel and Cathy, for their love and encouragement. 
 
 
v 
 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ...................................................................................................................... iii 
LIST OF TABLES ................................................................................................................................ vii 
LIST OF FIGURES .............................................................................................................................. viii 
FREQUENTLY USED ABBREVIATIONS ......................................................................................... ix 
CHAPTER 1. Introduction ...................................................................................................................... 1 
CHAPTER 2. Literature Review ............................................................................................................. 4 
Introduction ........................................................................................................................................ 4 
History of Tall Fescue and Fescue Toxicosis ..................................................................................... 4 
Introduction and Selection in the United States ............................................................................. 4 
Tall Fescue Toxicity ....................................................................................................................... 6 
Determining the Cause of Fescue Toxicity .................................................................................... 8 
Failure of Endophyte-Free Cultivars ............................................................................................ 13 
Symbiotic Relationship ................................................................................................................ 14 
Success of Nontoxic Endophyte Cultivars ................................................................................... 16 
Ergot Alkaloids and Animal Toxicodynamics ................................................................................... 17 
Alkaloids in Medicine .................................................................................................................. 17 
Synthesis and Structure ................................................................................................................ 18 
Absorption .................................................................................................................................... 20 
Metabolism................................................................................................................................... 24 
Downstream Effects on Receptors ............................................................................................... 26 
Serotonin Receptors ..................................................................................................................... 28 
Adrenergic Receptors ................................................................................................................... 29 
Dopamine Receptors .................................................................................................................... 31 
Solutions for Fescue Toxicosis ......................................................................................................... 32 
Introduction to mTOR ....................................................................................................................... 34 
Upstream of mTORC1 ...................................................................................................................... 37 
Growth Factors ............................................................................................................................. 37 
Energy Status and Oxygen Levels ............................................................................................... 38 
Amino Acids ................................................................................................................................ 39 
Upstream of mTORC2 ...................................................................................................................... 40 
Downstream of mTORC1 .................................................................................................................. 41 
Protein Synthesis .......................................................................................................................... 41 
Lipid and Glucose Metabolism .................................................................................................... 43 
Regulation of Protein Turnover ................................................................................................... 44 
Downstream of mTORC2 .................................................................................................................. 45 
Physiological roles of mTOR ............................................................................................................ 45 
vi 
 
Glucose Homeostasis ................................................................................................................... 46 
Skeletal Muscle and Whole-Body Metabolism ............................................................................ 48 
Adipogenesis and Lipid Homeostasis .......................................................................................... 49 
Conclusion ........................................................................................................................................ 50 
CHAPTER 3. Impact of Ergot Alkaloid and Estradiol 17B on Whole-Body Protein Turnover and 
Expression of mTOR Pathway Proteins in Muscle of Cattle ................................................................ 53 
Introduction ...................................................................................................................................... 53 
Materials and Methods ..................................................................................................................... 55 
Animal Management .................................................................................................................... 56 
Experimental Design and Procedures .......................................................................................... 56 
Measurement of Protein Turnover ............................................................................................... 58 
Calculation of Protein Turnover ................................................................................................... 60 
Muscle Biopsies ........................................................................................................................... 60 
Western Immunoblot Analysis ..................................................................................................... 62 
Plasma Analysis ........................................................................................................................... 65 
Data Analysis ............................................................................................................................... 66 
Results ............................................................................................................................................... 68 
Plasma Prolactin ........................................................................................................................... 69 
Protein Turnover .......................................................................................................................... 69 
Plasma Glucose ............................................................................................................................ 70 
Plasma Insulin .............................................................................................................................. 70 
Western Immunoblots .................................................................................................................. 71 
Discussion ......................................................................................................................................... 74 
Plasma Prolactin ........................................................................................................................... 75 
Dry Matter Intake and Weight Gain ............................................................................................. 76 
Glucose Homeostasis ................................................................................................................... 77 
Protein Turnover .......................................................................................................................... 82 
Western Immunoblots .................................................................................................................. 86 
Conclusion ........................................................................................................................................ 91 
CHAPTER 4. Summary and Conclusions ........................................................................................... 105 
APPENDIX ......................................................................................................................................... 109 
A. 1 Antibody Validations for Western Blot Analysis ..................................................................... 109 
A.1.a mTOR Antibody Validation ............................................................................................. 109 
A.1.b. p70-S6 Kinase Antibody Validation ............................................................................... 112 
A.1.c. 4E-BP1 Antibody Validation........................................................................................... 115 
A.2. Normalization to Total Protein ............................................................................................... 118 
LITERATURE CITED ....................................................................................................................... 121 
VITA ................................................................................................................................................... 139 
 
vii 
 
LIST OF TABLES 
Table 3.1. Composition of experimental diet fed to steers ............................................... 93 
Table 3.2  Prolactin area under the curve, dry matter intake, body weight at enrollment, 
body weight change, and average daily gain in steers treated with bromocriptine and 
estradiol/TBA implants ..................................................................................................... 94 
Table 3.3  Protein metabolism in steers treated with bromocriptine and estradiol/TBA 
implants ............................................................................................................................. 95 
Table 3.4 Area under the curve and peak height of plasma glucose from steers treated 
with bromocriptine and estradiol implants before and following an IV glucose bolus .... 95 
Table 3.5  Area under the curve, peak height, and time to peak of plasma insulin from 
steers treated with bromocriptine and estradiol implants before and following an IV 
glucose bolus ..................................................................................................................... 96 
Table 3.6  Relative abundance in arbitrary units of activated, phosphorylated, and total 
mTOR proteins in muscle of steers treated with bromocriptine and estradiol implants 
before (pre) and in response (post) to an IV glucose bolus .............................................. 97 
Table 3.7  Relative abundance in arbitrary units of activated, phosphorylated, and total 
S6K1 proteins in muscle of steers treated with bromocriptine and estradiol implants 
before (pre) and in response (post) to an IV glucose bolus .............................................. 98 
Table 3.8  Relative abundance in arbitrary units of activated, phosphorylated, and total 
4E-BP1 proteins in muscle of steers treated with bromocriptine and estradiol implants 
before (pre) and in response (post) to an IV glucose bolus .............................................. 99 
 
 
 
 
  
 
 
 
 
 
 
viii 
 
LIST OF FIGURES 
Figure 2.1  Ergot alkaloids produced by endophytic fungi of the genus Epichloë in 
infected plants ................................................................................................................... 51 
Figure 2.2  Signaling pathways contributing to muscle protein synthesis ........................ 52 
Figure 3.1  Mean plasma concentrations of prolactin (ng/mL) ...................................... 100 
Figure 3.2  Mean plasma concentration of glucose (mg/dL) .......................................... 101 
Figure 3.3  Mean plasma concentration of insulin (µIU/mL) ......................................... 102 
Figure 3.4  Representative graph of the interaction between pre-infusion levels of 
phosphorylated mTOR and bromocriptine treatment on post-infusion levels of 
phosphorylated mTOR .................................................................................................... 103 
Figure 3.5  Representative graph of the interaction between pre-infusion levels of total 
4E-BP1 and bromocriptine treatment on post-infusion levels of total 4E-BP1 .............. 104 
Figure A.1.1  Example gel showing the location of the band for phosphorylated mTOR 
and its disappearance when incubated with the antigen ................................................. 111 
Figure A.1.2  Example gel showing the location of the band for total mTOR and its 
disappearance when incubated with the antigen ............................................................. 112 
Figure A.1.3  Example gel showing the location of the band for phosphorylated p70 S6K 
and its disappearance when incubated with the antigen ................................................. 114 
Figure A.1.4  Example gel showing the location of the band for total p70 S6K and its 
disappearance when incubated with the antigen ............................................................. 115 
Figure A.1.5  Example gel showing the location of the band for phosphorylated 4E-BP1 
and its disappearance when incubated with the antigen ................................................. 117 
Figure A.1.6  Example gel showing the location of the band for total 4E-BP1 and its 
disappearance when incubated with the antigen ............................................................. 118 
Figure A.2.1  Representative image of the total protein stain ........................................ 120 
 
 
ix 
 
FREQUENTLY USED ABBREVIATIONS 
E-  Endophyte-free 
E+  Endophyte-infected 
KY-31  Kentucky-31 
5-HT  5-hydroxytryptamine (serotonin) receptor 
D2  dopamine receptor 2 
h  Hour 
d  Day 
min  Minute 
Da  Dalton 
N  nitrogen 
DM  dry matter  
DMI  dry matter intake 
ADG  average daily gain  
BW  body weight 
IVGTT intravenous glucose tolerance test 
AUC  Area Under the Curve 
TBA  Trenbolone Acetate 
GH  Growth Hormone 
IGF-1  Insulin-like Growth Factor-1 
BROMO Bromocriptine 
B+I  Bromocriptine and Estradiol Implant 
CON  Control 
IMP  Estradiol Implant 
1 
 
CHAPTER 1. INTRODUCTION 
 The most important pasture forage in the United States is the cool-season grass 
tall fescue (Festuca arundinacea) (Hoveland, 2009). Predominantly grown in the 
southeastern region of the country, tall fescue occupies 12 to 14 million ha and supports 
millions of cattle and other livestock (Buckner et al., 1979). Following the release of the 
Kentucky-31 cultivar, tall fescue experienced a meteoric rise in popularity due to its 
adaptability, persistence under heavy grazing, and extended growing season (Buckner et 
al., 1979). But even as tall fescue spread, it was gaining a reputation for causing poor 
animal performance despite appearing to be a nutritionally ideal forage for grazing. The 
multifaceted syndrome it caused was termed fescue toxicosis. Researchers discovered 
that grass infected with the endophytic fungi Epichloё coenophiala, which produces a 
variety of toxic ergot alkaloids, was responsible for fescue toxicosis; and that a 
mutualistic relationship between the fungus and tall fescue gave the plant its exceptional 
survivability (Bacon et al., 1977; Bacon and Seigel, 1988). 
 Fescue toxicosis is seen in cattle grazing fescue infected with high levels of 
endophyte, and the symptoms are generally categorized into three syndromes: fescue 
foot, fat necrosis, and summer slump. The most notable symptoms of affected animals 
include: elevated respiration rate and gangrene of the extremities, failure to shed the 
winter haircoat, heat intolerance, and reductions in weight gains, feed intake, 
reproductive efficiency, and milk production (Hoveland, 2009). This disease is the largest 
animal health related production cost in the grazing industry, and when considering its 
impact on all livestock species, the combined annual loss to the industry from fescue 
toxicosis likely exceeds $1 billion (Strickland et al., 2011). 
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 Ergot alkaloids liberated from forage in the gastrointestinal tract are considered 
the causal agents of the animal disorders associated with tall fescue consumption. Their 
diverse biological effects are directly related to the structural similarities between ergot 
alkaloids and the biogenic amine neurotransmitters norepinephrine, dopamine, and 
serotonin (Berde and Stürmer, 1978). This allows alkaloids to bind to multiple receptors 
associated with these neurotransmitters, which are located throughout the body, and 
prevent them from performing correctly. For example, interference with serotonin and 
adrenergic receptors has been shown to cause vasoconstriction of bronchial, 
subcutaneous and peripheral blood vessels; this is believed to be the cause of the 
respiratory and circulatory issues that are common in affected animals (Oliver, 1997; 
Dyer, 1993). A classic indication of fescue toxicosis is the sharp reduction in serum 
prolactin, which is caused by activation of dopamine receptors by ergot alkaloids (Schillo 
et al., 1988). 
 Since cattle exposed to ergot alkaloids have such pronounced losses in weight 
gain, there have been many attempts to improve their performance. Use of steroidal 
implants in stocker cattle is one approach that has been shown to increase ADG in 
animals grazing infected pasture (Brazle and Coffey, 1991; Beconi et al., 1995; Aiken et 
al., 2006; Carter et al., 2010). Davenport et al. (1993) demonstrated that cattle grazing 
endophyte-infected pastures not only had lower rates of gain compared to controls, but 
also exhibited a slight decrease in IGF-1 responsiveness to estradiol-17β. IGF-1 is an 
important stimulator of the mTOR pathway, which in turn is responsible for protein 
synthesis and muscle gain in growing animals (Yoon, 2017). Ergot alkaloids and 
structurally similar chemicals (indoles) have been shown to inhibit the growth hormone 
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axis (Flückiger et al., 1978) and the mTOR pathway (Ahmad et al., 2013), respectively, 
in other species. Research investigating the effects of ergot alkaloids on net protein 
synthesis and the mTOR pathway in cattle is severely lacking. The objective of the 
current study was to determine if fescue-derived alkaloids decrease muscle protein 
synthesis though inhibitory action on the mTOR pathway via a direct effect on signal 
proteins, and if these negative effects can be alleviated by implantation with anabolic 
agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
CHAPTER 2. LITERATURE REVIEW 
Introduction 
One of the most wide-spread and heavily utilized forages in the United States is 
the cool-season grass, tall fescue (Festuca arundinacea). To some extent, all sectors of 
the livestock and equine industries rely on tall fescue for grazing, but beef cow-calf 
operations became especially dependent on the grass after its widespread introduction to 
the country during the mid-20th century. The species appeared to be well-suited for 
livestock grazing because of its hardiness, nutritive qualities, and ease of cultivation, 
however, consumption of tall fescue quickly became associated with poor animal health 
and performance. The multifaceted syndrome, dubbed tall fescue toxicosis, can be costly 
to producers and has garnered attention from scientists for many years. Once it was 
recognized that the disease was caused by ergot alkaloids, which are present in most tall 
fescue through its relationship with the endophytic fungus Epichloё coenophiala, 
research began to focus on how alkaloid consumption altered body homeostasis in order 
to fully understand the underlying mechanisms of fescue toxicosis. With regard to their 
influence on essential metabolic pathways, such as protein expression, insulin signaling, 
and lipid metabolism, there is still much to be discovered and their effects are virtually 
unknown at the present time. 
History of Tall Fescue and Fescue Toxicosis 
Introduction and Selection in the United States 
Even though tall fescue is the most important pasture grass in the United States, 
its introduction into the country is shrouded in speculation. The story likely begins with 
another native of Europe and close relative, meadow fescue, which was first introduced 
5 
 
into cultivation around 1820, but has long been recognized for its value as a forage plant 
(Smith, 1899). Almost all the meadow fescue seed planted in the US until the late 1880s 
was imported from England, tall fescue was likely a contaminant in that seed (Vinall, 
1909). These accidental additions to meadow fescue pastures were quickly recognized for 
their ability to thrive even in conditions where meadow fescue began to wane. By 1900 it 
was proving its worth for pasture and mowing in grass trials in Kentucky (Garman, 1900) 
and Virginia (Kennedy, 1900); and was praised for its superior growth, height, 
competitive ability, and drought tolerance. 
The popularity of tall fescue was not fully realized until the release of two 
cultivars in the 1940s, Alta and Kentucky 31 (KY-31). Starting in 1918, the ecotype Alta 
was selected for winter hardiness, persistence, and ability to remain green during the dry 
summers of western Oregon; and then released cooperatively by the Oregon Agricultural 
Experiment Station and the USDA (Cowan, 1956). Alta was planted throughout the 
Pacific Northwest and intermountain regions of the western United States. The ecotype, 
KY-31 was first collected in 1931 from a mountain pasture in Menifee County, 
Kentucky. The population had been under natural selection on the site when the property 
was purchased in 1875 and local farmers held it in high regard for pasture and erosion 
control (Fergus and Buckner, 1972). The Kentucky Agricultural Experiment Station 
conducted lengthy tests of the cultivar, and it was released in 1942. KY-31 was noted for 
its dependability, adaptability to a wide range of soils, and ability to provide grazing over 
much of the year (Buckner et al., 1979). With the release of KY-31, the popularity of tall 
fescue soon eclipsed that of other cool season perennial grasses, mostly because of its 
greater persistence in pastures compared to other species. These qualities can be 
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attributed to its course, deep root system which develops a thick sod; allowing it to grow 
on sites with moist, heavy soils, that are often waterlogged or flooded, making tall fescue 
particularly valuable for conservation purposes (Buckner et al., 1979). The previously 
barren and brown winter landscape of the southern United States was transformed during 
the 1940s and 1950s by the widespread planting of tall fescue for forage, soil 
conservation, roadside cover and turf (Hoveland, 2009). 
During the 30 years following the release of Alta and KY-31, tall fescue 
cultivation rapidly spread in the United States, until it was the predominant cool-season 
perennial grass. In 1940 it grew on approximately 16,000 ha, over 1.6 million ha in 1956, 
and by 1973 it occupied an estimated 12 to 14 million ha; the species also spread from its 
original range in the transition zone and is now grown from Florida to Canada in a wide 
range of climatic conditions (Cowan, 1956; Buckner at al., 1979).  
Tall Fescue Toxicity 
With the widespread use of tall fescue for pasture came the rise of a conglomerate 
of health issues that were discovered to be a direct result of livestock consuming the 
grass. By the 1950s, fescue had gained a reputation for causing problems in animals that 
resulted in poor performance (Pratt and Haynes, 1950). This puzzled animal scientists 
since well-managed fescue was a high-quality forage when it came to crude protein, 
digestible dry matter, amino acid and mineral content, and should result in good animal 
performance (Bush and Buckner, 1973). The first health issue to be reported and 
associated with fescue pastures was the syndrome fescue foot. In the summer months, 
animals consuming large amounts of tall fescue struggle to dissipate heat, resulting in 
excessive panting and spending extended time in shade or in ponds; while in the winter, 
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animals cannot maintain peripheral body temperature, which can result in frost bite and 
subsequent loss of ears, tail switches, and hooves (Jacobson et al., 1963). This was first 
reported in Australia by Cunningham (1949) and then in New Zealand by Pulsford 
(1950), who said it had been known by stockman for many years. In the United States the 
first report came from Colorado in 1952; it had been recognized for about 30 years, but 
was confused with other conditions like foot rot, frozen feet, or ergot poisoning 
(Goodman, 1952).  
The second syndrome, known as fat necrosis, occurs where high rates of nitrogen 
fertilizer are applied to tall fescue pasture; mainly from poultry litter or other manure. 
Hard fat accumulates in the abdominal cavity of cattle, which do not show symptoms 
until vital body processes are affected, most frequently digestive upset occurs when the 
necrotic tissue constricts the intestines (Bush et al., 1979). Fat necrosis may also interfere 
with the functions of the kidney and heart, as well as cause difficult births if the birth 
canal is surrounded (Edgson, 1952; Williams et al., 1969) This problem was first 
clinically diagnosed by Williams et al. (1969) in the United States in 1967. 
The third syndrome, first described by Robbins in 1973 is commonly called 
summer slump, because it is exhibited especially during the summer, when temperatures 
are highest (Robbins, 1983). Symptoms are varied and include nervousness, elevated 
body temperature, intolerance to heat, failure to shed winter coat, depressed feed intake, 
poor weight gains and milk production, excess salivation, and reduced conception rates 
(Hoveland et al., 1983). The major economic losses to the United States beef industry 
associated with consumption of endophyte infected tall fescue can mostly be attributed to 
this disorder (Sleper and West, 1996). Poor performance has also been observed in other 
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livestock. Dairy cattle grazed on tall fescue have lower milk production than on other 
grasses (Seath et al., 1956) and mares have higher foal mortality rates and agalactia 
(Putnam et al., 1990). 
Even though financial losses attributed to tall fescue are great, producers often do 
not recognize the problem, given that the signs can go undetected until they become 
severe, this makes fescue toxicosis the largest animal health related production cost in the 
grazing industry (Strickland et al., 2011). A survey in 1993 of state extension specialists 
where tall fescue is most common, showed that losses from reduced conception rates and 
weaning weights in beef cattle total $609 million annually (Hoveland, 1993). Beef 
stocker grazing on tall fescue is also unprofitable because of low daily gains, so it is 
rarely done, forcing producers to graze cattle on more expensive annual pastures. Losses 
to the horse industry from fescue toxicosis are exceedingly difficult to estimate, but 
nearly all the states reported reproduction issues. Compared to those of cattle, increased 
foal mortality may not result in as many deaths, but considering the price of horses, 
especially in the thoroughbred industry, these losses still hold a high monetary value on 
an individual basis. When regarded in today’s dollars and considering the impact on the 
equine and small ruminant industries, the combined annual loss to the livestock industry 
from fescue toxicosis likely exceeds $1 billion (Strickland et al., 2011). The cost of this 
disease drove researchers to uncover the root of these syndromes.  
Determining the Cause of Fescue Toxicity 
During the 1950s-1970s, research erroneously concentrated on possible culprits 
such as external plant fungi, plant alkaloids, anions, and toxins produced in the rumen, 
this delayed any real breakthroughs in the cause of fescue toxicity (Bush et al., 1979). 
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Dissection of the limbs of cattle experiencing lameness while consuming tall fescue 
revealed that the toxic agent in the grass caused vasoconstriction and thrombosis of the 
arteries, which obstructed blood flow. This, plus low environmental temperatures were 
determined to cause the gangrene of the extremities associated with fescue foot (Jensen et 
al., 1956). Chemical tests isolated several alkaloids from toxic tall fescue that were 
similar to those found in the ergot fungus, Claviceps purpurea, but no ergot sclerotia 
from that fungus were detected by visual examination (Trethewie et al al., 1954; Maag 
and Tobiska, 1956). Discovering ergot alkaloids in fescue was very important, but these 
early reports were mostly ignored by scientists working on fescue toxicosis at the time. 
Until a suitable bioassay could be perfected, progress in isolating the toxic component 
was very slow. The syndrome was experimentally produced in cattle by Jacobson et al. 
(1963), using an extract chemically fractioned from toxic forage; this method allowed 
them to define the physiological effects of tall fescue consumption. They also 
demonstrated that poor circulation resulting in gangrene of the extremities was not caused 
by an abrupt halt in blood flow, since gangrene only became apparent after about ten 
days. Their findings clearly indicated that there was vasoconstriction, but the specific 
causes were still unknown. 
Progress began in 1973, when J. D. Robbins, J. K. Porter, and C. W. Bacon 
focused their research on a toxic tall fescue pasture in northern Georgia. From that single 
pasture, this group of scientists was able to isolate several species of fungi, which served 
as the basis for a multitude of grass toxicity studies. Three species were isolated from this 
pasture, all belonging to the tribe Balansiae: Balansia epichloe (Weese) Diehl, B. 
henningsiana Moell, and Myriogensopora atrementosa (Berk. & Curt.) Diehl. Unlike 
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their saprophytic or pathogenic relatives, these species are unique because they are 
endophytic, and not virulent to their grass hosts. The species of Balansia primarily 
associate with warm season weed and rangeland grass species, such as bentgrass, 
bluestem, crowngrass, and others, which are commonly found in pastures of tall fescue 
and contribute to the toxicity of tall fescue during the summer months (Bacon, 1995). 
The most important series of toxicological studies during this time were 
conducted primarily by J. K. Porter. He was able to demonstrate that these endophytic 
species of fungi were toxic and could potentially synthesize ergot alkaloids. Fungal 
spores were collected and allowed to germinate, then cultures were incubated in 
appropriate medium so alkaloids could be produced in vitro. Inocula prepared from these 
cultures, containing indole compounds, proved to be toxic to chicken embryos (Bacon et 
al., 1975). Chemical extraction isolated four clavine-type alkaloids from cultures of B. 
epichloe: chanoclavine (I), agroclavine, penniclavine and elymoclavine, which are 
commonly found in species of Claviceps. Chanoclavine (I) was also produced by B. 
claviceps, B. henningsiana and B. strangulans. The lysergic acid derivatives, ergonovine 
and ergonovinine, were isolated from B. claviceps and B. epichloe (Bacon et al., 1979; 
Porter et al., 1979a, 1979b); this was the first demonstration of these compounds in fungi 
outside the genus Claviceps.  These findings suggested that ergot alkaloids produced by 
these species may be involved in cattle toxicity syndromes where species of Claviceps 
are absent. 
After the discovery of endophytic Balansia species in warm season grasses and 
the demonstration that biosynthesis of ergot alkaloids was limited to the family 
Clavicipitaceae, tribe Balansiae, this group of researchers began searching for a species 
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of Balansia or similar endophyte in the toxic tall fescue in the pasture in north Georgia. A 
2-yr observation of the pasture grazed by cattle suffering fescue toxicity symptoms, did 
not reveal a specific Balansia taxon in the grass, but they did isolate another fungal 
endophyte, which at the time was believed to be Epichloё typhina (Bacon et al., 1977). 
The cattle suffering toxicosis grazed pastures with infection rates of 100%, while pastures 
with cattle in good condition had infection rates of 0-50%. The identity of the tall fescue 
endophyte, which was symptomless and nonsporulating, was originally reported to be E. 
typhina based on the work of Sampson (1933). This was challenged later by Morgan-
Jones and Gams (1982), who found the endophyte to be an anamorph of E. typhina and 
not identical. To classify the anamorphs of Epichloё, they created the section Albo-lanosa 
within the genus Acremonium and named the endophyte A. coenophialum. In 1996, a 
phylogenic examination of species in Acremonium determined that the anamorphic tall 
fescue species was classified inappropriately and proposed the monophyletic genus 
Neotyphodium (Glenn et al., 1996). The species was reclassified again in 2014, when a 
nomenclatural ruling called for Epichloё and its anamorphs in Neotyphodium to be placed 
into one genus (Leuchtmann et al., 2014). Thus the tall fescue endophyte is currently 
named Epichloё coenophiala. Further evidence from grazing trials confirmed that this 
fungal endophyte was the causal agent of fescue toxicosis. 
A 3-year trial in central Alabama showed that steers in paddocks with 18% E. 
coenophiala infestation, had 51% higher average daily gains (ADG) than steers in 
paddocks with 80% infestation (Hoveland et al., 1980). These findings were confirmed 
by two more trials in the following years. One demonstrated again that steers grazing 
fescue with low infestation rates would have higher gains. In this case, steers in paddocks 
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with 5% infestation, had 66% greater ADG and 28% greater gain per acre than animals in 
paddocks with 94% infestation (Hoveland et al., 1983). Another produced similar results 
by feeding steers fungus-free and infested KY-31 hay and seed; the presence of the 
fungus in both the hay and the seed diets decreased daily gains and feed intake (Schmidt 
et al., 1982). Steers eating infested grass, hay, or seed, showed typical signs of toxicosis; 
elevated body temperature, rough coat that did not shed, excessive salivation, and 
nervousness; while steers on low-endophyte grass or fungus-free feed were in excellent 
condition, tolerated heat, and showed no signs of nervousness (Hoveland et al., 1983; 
Schmidt et al., 1982). The association of endophyte infection with tall fescue toxicosis in 
cattle (Hemken et al., 1981; Hurley et al., 1981), sheep (Stilham et al., 1982), and horses 
(Monroe et al., 1988; McCann et al., 1992), was proven by several others in the following 
years, further confirming that endophyte-infected tall fescue is toxic to livestock. 
Even though ergot alkaloids were produced in culture from the tall fescue 
endophyte in 1979, the toxins were not detected in plants until 1985. Using tandem mass 
spectrometry, significant levels of ergopeptine alkaloids were detected in extracts from 
tall fescue pastures with recent histories of toxicity in cattle. Ergot alkaloids were present 
in all aboveground parts of the plant, with 10-50% being ergopeptines. Specifically, 
ergovaline, ergosine, ergonine, ergoptine, and ergocornine were reported, with the 
predominant type being ergovaline at 84-97% of the total ergopeptine fraction (Lyons et 
al., 1986). Small amounts of ergotamine have also been found in endophyte infected 
fescue (Yates et al., 1985). Historically, ergovaline has been recognized as the major 
ergopeptine alkaloid produced by the endophyte, and the primary cause of reduced 
plasma prolactin and vasoconstriction (Dyer, 1993). However, it is unwise to overlook 
13 
 
the other ergopeptine alkaloids and metabolites found in infected tall fescue. In the past it 
has been difficult to study differences between specific alkaloids due to the lack of 
commercially available ergovaline. 
A survey of seed and pasture from all over the United States was conducted in 
1987 to detect potentially damaging levels of endophyte. They found that about 95% of 
tall fescue pastures showed varying degrees of endophyte infection. This widespread 
occurrence was largely due to the overwhelming acceptance of KY-31 from its release in 
1943 into the 1960s; this cultivar also had a higher level of infection than most of the 
others surveyed (Shelby & Dalrymple, 1987).  The species was widely dispersed in the 
eastern part of the country and during this time the forage industry was becoming more 
aware of the losses sustained when cattle grazed on infected fescue. At the time it was 
thought that the solution was to remove the endophyte from tall fescue altogether. 
Failure of Endophyte-Free Cultivars 
As researchers studied grass endophytes, they realized they were sensitive to 
storage conditions. When tall fescue seed was exposed to hot, humid conditions during 
storage, the endophyte would die, but the seed remained viable. In the past, the high 
demand for KY-31 seed meant that most of what was harvested in the summer was sold 
and planted within months, so the seed was not exposed to conditions needed to kill the 
toxic endophyte, which facilitated its spread. Now with a way to remove the endophyte, 
new cultivars of fungus free and nontoxic tall fescue were developed, the first being AU 
Triumph, which was released in 1982 (Hoveland et al., 1982). Thorough testing showed 
excellent animal performance on pastures of AU Triumph and farmers readily replaced 
toxic pastures with endophyte-free seed. Unfortunately, grazing practices were not altered 
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for these E- pastures and within a few years, farmers noticed that unlike the famous KY-
31, the new cultivar could not persist through drought and over grazing. Even pastures 
planted with other cultivars containing low levels of endophyte infestation (<25%) were 
outcompeted by pastures that were highly infected (90+%), during periods of stress. The 
loss of stand in the low-infested pastures indicated a competitive advantage for infected 
tall fescue (Read and Camp, 1986). Selection for more persistent endophyte free varieties 
was attempted but was unsuccessful, and it became apparent that agronomic performance 
was enhanced by a mutualistic relationship between tall fescue and the endophyte fungus. 
While endophytes had previously been considered parasitic, evidence that they conferred 
superior fitness to the host plant and that these benefits were multifaceted were piling up. 
Symbiotic Relationship 
 Tall fescue research up to this point had mostly focused on the detrimental effects 
the endophyte had on livestock production, so the biological significance of the fungus 
was not fully understood. This was quite apparent after the premature release of the E- 
tall fescue cultivars and their subsequent failure in stressful environments. The 
ultrastructural association between grass and fungus, as well as the growth and survival 
benefits granted to infected grasses, suggested that a symbiotic relationship formed early 
in their respective evolutions (Bacon and Seigel, 1988). E. coenophiala has a relatively 
simple life cycle. The species is asexual, so the only route of dissemination is by maternal 
transmission through host embryos. Fungal hyphae colonize seeds in inflorescences early 
in development, and occupy the embryonic axis, including the shoot atypical meristem 
and the scutellum (Christensen and Voisey, 2009). The endophyte lies dormant in the 
seeds until the they are planted and germinate, or it dies in storage. Once germinated, 
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elongated hyphal filaments colonize the extracellular spaces of leaf sheaths, meristems, 
and internodes of growing stems, but not roots, and absorb nutrients directly through the 
hyphal wall (Christensen and Voisey, 2009). In this relationship, the fungus benefits by 
receiving nutrients, protection, and a means for reproduction and dissemination, while the 
host plant receives a variety of advantages in overall vigor along with protections against 
biotic attack. Several ecological and physiological processes in the fescue plant were 
found to be influenced by symbiosis with the endophyte; but a single mechanism by 
which the endophyte promotes host fitness is not apparent (Belesky and West, 2009). 
 Since its accidental introduction, tall fescue has been celebrated for stand 
persistence and tolerance of grazing during dry conditions, these are major benefits of 
endophyte infestation. The mechanisms enabling this ability are complex and not fully 
understood. During severe water deficit, endophyte infected plants showed enhanced 
tiller density and survival, which conferred population stability and proved advantageous 
in the following year (West et al., 1993). Greenhouse experiments showed that E+ plants 
were more productive than E- plants of the same cultivar at mild moisture stress (-0.05 
MPa). During severe moisture stress (-0.5 MPa), 75% of the E- plants died, while all the 
E+ plants survived. Infected plants often showed greater shoot mass and tiller numbers 
than endophyte-free, and previously drought stressed infected plants also had much 
greater regrowth after harvest (Arachevaleta et al., 1989). This fitness helped tall fescue 
spread until it was the premier grass in the United States and prevail as a cool-season 
species in states south of its typical area of adaptation. The transition zone in the United 
States represents a progression, from north to south, of increasing summer water deficit 
caused by high evaporative demand and low soil water-holding capacity, such as the 
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rocky soils in the Ozark Highlands and southern Appalachian Mountains. The endophyte 
helps tall fescue compete and survive in this transition zone when growing conditions 
favor other plant species (Belesky and West, 2009). 
 Indirectly, the endophyte also enhances host persistence by deterring herbivory. 
The production of certain chemicals, including alkaloids, deters grazing animals, insects, 
and nematodes. This allows the plant to retain high leaf area and strong root systems, thus 
avoiding energy depletion and maintaining the ability to acquire water and nutrients in 
stressful conditions. Infected fescue gains resistance to herbivorous insects which would 
deplete the leaves (Clay et al., 1985) and nematodes which would destroy the root mass 
(West et al., 1988). These findings led to a greater understanding of the complex 
relationship between the endophyte and tall fescue and had monumental implications for 
cultivar development and pasture management. 
Success of Nontoxic Endophyte Cultivars  
 In the late 1980s, Joe Bouton listened to a talk given by Gary Latch, a researcher 
from New Zealand, about endophytic fungi infection in tall fescue’s close relative, 
perennial ryegrass. Afterwards, while Bouton and Latch discussed their research, Latch 
mentioned that he had identified endophytes in perennial ryegrass that did not produce 
alkaloids toxic to livestock, which were the cause of ryegrass staggers in sheep. What 
made this discovery unique was that while the ryegrass endophyte didn’t produce the 
toxic alkaloid lolitrem B, it still produced peramine, a deterrent against the main insect 
pest of perennial ryegrass in New Zealand, the Argentine stem weevil (Latch, 1997). This 
was unlike the recently developed tall fescue that was endophyte-free, so could not 
produce any protective alkaloids, reducing its survivability and use as a pasture grass. 
17 
 
Bouton was able to visit New Zealand several years later in order to work with Latch and 
his associates; together they isolated a naturally occurring, nontoxic strain of endophyte. 
The result was the AR542 endophyte, which does not produce ergot alkaloids, now 
marketed as MaxQ in the United States (Bouton et al., 2002). The strategy was to kill the 
toxic endophyte in seed from the best available tall fescue cultivars, then reinfect 
seedlings with the non-ergot alkaloid producing endophyte, thus eliminating the toxic 
effects in livestock, while maintaining the symbiotic benefits between endophyte and 
grass. The main commercial “novel” product on the market is Jesup MaxQ, the result of 
reinfecting the tall fescue cultivar Jesup. This novel cultivar demonstrated stand survival 
equal to toxic E+ tall fescue, but decidedly better than E- fescue (Bouton et al., 2002). 
Jesup MaxQ also did not express the effects of ergot alkaloids on grazing animals, so had 
strikingly positive effects on animal performance, compared to E+ pasture (Bouton et al., 
2002; Parish et al., 2003a; 2003b). To date, this cultivar has produced no animal toxicity 
problems. Currently, the most dependable method for eliminating animal losses from tall 
fescue toxicosis is replacing toxic tall fescue pastures with novel cultivars. Replacement 
of pastures is a substantial up-front cost, but improvement in animal production will 
generously repay the investment. 
Ergot Alkaloids and Animal Toxicodynamics 
Alkaloids in Medicine 
Alkaloids are organic, N-containing, basic compounds, which are naturally 
produced by a variety of organisms, most often plants. Many plant-derived alkaloids are 
familiar, as they have important medical uses, such as morphine (analgesic), quinine 
(antipyretic/antimalarial), atropine (anticholinergic), and vincristine (antitumor). Others 
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are addictive like cocaine, heroin, nicotine, and caffeine; or very toxic like strychnine and 
coniine. The multitude of ergot alkaloids were named for the ergot fungus Claviceps 
purpurea, their first known producer and cause of several epidemics during the middle 
ages. Ergot alkaloids all contain a tetracyclic ergoline ring system or a biosynthetic 
precursor; enzymatic modification of the ergoline ring results in a plethora of bioactive 
natural products that can be used as pharmaceutical treatments for a variety of ailments 
(Gerhards et al., 2014). They have a strong affinity for serotonin, dopamine and 
adrenergic receptors because of structural similarities with neurotransmitters, so they can 
be potent drugs; for example, methylergometrine is used to stop bleeding after childbirth, 
ergotamine to treat migraines, and bromocriptine is used to treat Parkinson’s disease 
(Gerhards et al., 2014). Those that have been isolated from grass infected with the 
endophyte Epichloё coenophiala are considered the causal agents of animal disorders 
associated with tall fescue consumption and include clavines, lysergic acid, simple 
lysergic acid amides, and ergopeptines (Bush and Fannin, 2009). 
Synthesis and Structure 
Biosynthesis of ergot alkaloids was first studied in Claviceps purpurea, the fungus 
responsible for ergotism and initial suspect for the cause of fescue toxicosis. The 
precursors of ergot alkaloids are tryptophan and the mevalonic acid derivative 
dimethylallyl pyrophosphate (DMAPP), which originates from acetate metabolism (Bush 
et al., 1997; Garner et al., 1993). These are converted to dimethylallyl-tryptophan 
(DMAT) by DMAT synthase, in what is probably the limiting step in ergot alkaloid 
formation (Bush et al., 1997). N-methylation and C-oxidation of DMAT leads to 
formation of a diene, which is then epoxidized, resulting in spontaneous cyclization of 
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the C-ring and release of an α-carboxyl group, yielding chanoclavine I; the first of the 
clavines (Schardl and Panaccione, 2005).  The cyclization of the D-ring of chanoclavine I 
is catalyzed sequentially by chanoclavine I dehydrogenase, a flavine-dependent 
oxidoreductase, then a reductase, to produce the tetracyclic clavine alkaloid, agroclavine 
(Florea et al., 2017). Agroclavine is transformed into lysergic acid by the NADPH-
dependent cytochrome P450, CloA, which is responsible for three rounds of 2-electron 
oxidations (Florea et al., 2017). The only difference between the clavines and the 
derivatives of lysergic acid are the isomerization of the double bond in the D ring of 
agroclavine from the 8, 9 to the 9, 10 position when the lysergic moiety is formed (Hill, 
2005). 
A variety of amide derivatives of lysergic acid have been characterized in 
endophyte-infected plants; the simplest being ergolines and the most complex being 
ergopeptines. Ergoline alkaloids have a simple chemical structure attached to the 8 
carbon; lysergic acid has a carboxylic acid and lysergol has a methyl alcohol in that 
position, while others may include hydrazide, azide, or amide groups (Rutschmann and 
Stadler, 1978). Ergopeptine alkaloids are created when a tricyclic peptide ring is attached 
via a carbonyl at the 8 position in the D ring of lysergic acid (Hill, 2005). Three amino 
acids form a tricyclic peptide, proline always occupies position 3, while the amino acids 
in positions 1 and 2 will differ depending on the alkaloid formed (Bush and Fannin, 
2009). Biosynthesis of ergopeptide lactams, the immediate precursors of ergopeptines, 
are catalyzed by the nonribosomal peptide synthetase (NRPS) enzyme, lysergyl peptide 
synthetase (LPS), which consists of two subunits (Florea et al., 2017). The subunit LpsB, 
has a single module that activates D-lysergic acid, and the subunit LpsA has three 
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modules that each specify a hydrophobic L-amino acid or an analog; once these four 
substituents are linked, they are released from the NRPS and the amino acids in position 
2 and 3 are cyclized to form the piperizinedione ring (Florea et al., 2017). EasH, a 
dioxygenase, catalyzes the oxidative cyclization of the amino acid in position 1, forming 
the final cyclol ring of an ergopeptine (Florea et al., 2017). Condensation of D-lysergic 
acid with alanine, valine, and proline for example, forms ergovaline, which as mentioned 
previously, is the most prevalent ergopeptine in E+ tall fescue. The R1 position can be 
occupied by alanine, valine or L-2-aminobutyric acid and the R2 position can hold valine, 
isoleucine, leucine, or phenyalanine (Berde and Stürmer, 1978), in order to produce other 
ergopeptines in E+ fescue, which include ergotamine, ergosine, ergocornine, ergocristine, 
ergokryptine, ergonine (Yates et al., 1985). 
Absorption 
Alkaloids must overcome several protective mechanisms the body has in place 
before they cause disruption in the physiological systems of an animal. These natural 
barriers include mechanisms of influx and efflux, biotransformation, impediments during 
transport such as the blood-brain and placental barriers, and physical elimination from the 
body (Strickland et al., 2011). In vivo evidence of ergot alkaloid absorption has relied on 
analysis of excretions and intake estimates in the live animal. Studies using radiolabeled 
ergot alkaloids in isotopic experiments in rats, dogs, and monkeys, found that the route of 
excretion of the ergot alkaloids are dependent on the molecular weight and polarity of the 
compound (Eckert et al., 1978). Alkaloids with a molecular weight of less than 350 Da 
(lysergic acid and its amides) are excreted in the urine, those between 350 and 450 Da are 
excreted in urine and bile, and those above 450 Da (ergopeptines) are excreted in the bile 
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and eliminated through feces (Eckert et al., 1978).  Samples of urine and bile taken from 
cattle grazing endophyte infested tall fescue demonstrated that 96% of the ergot alkaloids 
consumed will be excreted in the urine as lysergic acid derivatives and very little in the 
bile as ergopeptines (Stuedemann et al., 1998). The urine collected contained most of the 
ergot alkaloids consumed, suggesting that the excretory form of ergot alkaloids is either 
intact lysergic acid derivatives or biotransformed ergopeptine alkaloids. Ergopeptines are 
the major ergot alkaloid in tall fescue, not lysergic acid derivatives, so it is unlikely that 
the concentration in the forage is high enough to account for the differences between 
urinary and biliary excretion patterns (Stuedemann et al., 1998). Recovery of ergovaline 
was determined using samples taken from the abomasum and feces of sheep fed E+ and 
E- fescue seed; 47 to 63% was recovered in abomasal digesta, indicating a significant 
reduction in the foregut, but only 6 to 7% was recovered from the feces, indicating most 
of the remaining alkaloids were absorbed or metabolized in the intestines (Westendorf et 
al., 1993). Ergopeptines analyzed via HPLC in the feces of ergot-exposed dairy cattle 
showed that almost 24% of their ergopeptine intake was excreted in the feces (Schumann 
et al., 2009). A variety of factors could have contributed to the greater fecal recovery of 
ergopeptines by Schumann et al. (2009), such as digesta flow rates, rumen pH, and 
differing alkaloid profiles. These in vivo studies supported the conclusion that extensive 
absorption of ergot alkaloids from the gastrointestinal tract occurs in ruminants. 
 While many toxins and drugs are absorbed across the gastrointestinal epithelia 
through passive transport, the rate and magnitude of ergot alkaloid absorption is greatly 
affected by their solubility within the digestive tract and the extent of ionization, which in 
turn determines the partitioning of alkaloids between water and lipid phases (Eckert et al., 
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1978). Most of the ergot alkaloids are weak bases and possess both polar and nonpolar 
components, so their water/lipid partitioning and absorption are affected by the pH of the 
surrounding environment (Strickland et al., 2011). Since ergopeptines are charged at low 
pH, it’s assumed that they would not be absorbed in the acidic environment of the 
abomasum and gastric stomach, meaning absorption is confined to the forestomach, small 
intestine, and large intestine in ruminants, and the small intestine and large intestine in 
nonruminants (Strickland et al., 2011). The rumen of a forage fed animal is functionally 
more like the intestine than the gastric stomach. Ruminal pH is near neutral and the 
compartment lacks a mucosal layer, which is necessary in the gastric stomach to protect 
the lining from digesta. This permits nutrient transport across the epithelium of the rumen 
and the small intestine, making them the likely site of alkaloid absorption. 
Measuring absorption across the epithelia has proven difficult and has not been 
done directly in vivo, but in vitro studies have provided indirect evidence to support this 
theory. Ruminal, reticular, and omasal tissue from endophyte naïve sheep were used in 
parabiotic chambers by Hill et al. (2001) to determine absorption potential for several 
ergot alkaloids across forestomach tissue. Equimolar proportions of ergot alkaloids were 
added to the mucosal side of the tissues and the amount of alkaloid that appeared over a 4 
h period on the serosal side was measured. The rumen appeared capable of transporting 
approximately 25% more alkaloids than the omasum and approximately 600% more than 
the reticular tissues. The results also suggested that the ergoline alkaloids — lysergic 
acid, lysergol and ergonovine — were more likely to cross digestive barriers than 
ergopeptine alkaloids, specifically ergotamine and ergocryptine. Lysergic acid was 
transported at the highest rate in all tissues. This movement appeared to be through active 
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transport because alkaloid transportation was reduced in the presence of sodium azide, 
which killed the tissue (Hill et al., 2001). These findings were supported by Ayers et al. 
(2009) who again demonstrated that the primary alkaloid transported across forestomach 
tissues is lysergic acid and additionally found that ergovaline was not transported across 
ruminal or omasal tissues. This suggested that the small intestine may be the most 
important site for ergopeptine absorption in ruminants. However, studies examining the 
role of the ruminant hindgut in alkaloid degradation and absorption have not been 
conducted, making it difficult to definitively determine the path of ergot alkaloids 
through the body. 
Three potential routes were proposed by Klotz and Nicol (2016) for intact 
ergopeptines to take once they reach the small intestine. The first is that they go 
unabsorbed through the small intestine and continue to the large intestine, where they 
face possible metabolism by microbes in the hindgut but will eventually be excreted in 
the feces. The second is that ergopeptines are absorbed and transported via the mesenteric 
veins to the portal vein and the liver, where they undergo hepatic detoxification or 
excretion back into the intestines as bile. The alternative path is that ergopeptines are 
absorbed in the small intestine and transported via the lymphatic system, through the 
thoracic duct and into venous circulation at the subclavian vein; this would bypass first-
pass detoxification by the liver and allow ergopeptines to be systemically distributed via 
arterial blood, before detoxification by the liver. Considering lipids are regularly 
absorbed from the small intestine through lacteals leading to the lymphatic system in the 
form of micelles, and ergopeptines are lipophilic in nature, this route of absorption is 
likely to occur in ruminants (Klotz and Nicol, 2016). 
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Metabolism 
Ergot alkaloid metabolism in ruminants cannot be fully explained without 
considering the role played by the microorganisms responsible for pre-gastric 
fermentation of feedstuffs. The diverse microbial community of the rumen can catabolize 
substrates, like cellulose, and liberate compounds that are not otherwise accessible for 
mammalian digestion. Toxicants appear to be among those compounds. In vitro and in 
vivo fermentation studies have been used to elucidate the actions of microbes on fescue 
digestion and alkaloid metabolism in the rumen. When endophyte infested fescue was 
incubated with viable microbes in vitro, the concentration of soluble ergovaline decreased 
linearly as fermentation progressed, with only 5% remaining after 48 h of incubation 
(Moyer et al., 1993). The total amount of ergot alkaloids has been found to increase over 
time, with lysergic acid being the primary alkaloid in both in vitro and in vivo ruminal 
fluids. (Ayers et al., 2009). The digestion of ergovaline and production of lysergic acid 
has been investigated in vivo by De Lorme et al. (2007) as well. Sheep were fed 
endophyte infested hay then rumen fluid was sampled 0, 6, and 12 hours after feeding 
and analyzed for ergot alkaloids using HPLC; this was repeated on day 0, 3, and 28. 
Ruminal ergovaline concentrations increased from d 0 to 3 and d 3 to 28. It was not 
different before feeding to 6 hours but increased from 6 to 12 hours post feeding. 
Lysergic acid in the rumen fluid increased from day 0 to 3 but not between day 3 and 28; 
it also increased in the first 6 hours post feeding but not between 6 and 12 hours. Urine 
and fecal samples were also taken from these sheep and evaluated using HPLC. The 
results of this experiment supported those reported by Stuedemann et al. (1998). The 
amount of ergovaline excreted in the feces was less than what was consumed by the 
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lamb. Lysergic acid also appeared in the urine and the feces in greater amounts than what 
was in the feed. This indicated that lysergic acid was produced during digestion of fescue, 
most likely in the rumen, which previous research has shown is the likely place of 
absorption (De Lorme et al., 2007). These actions by microbes in the rumen increase the 
concentrations of ergot alkaloids available for absorption by the animal’s gastrointestinal 
tract and subsequently increase the chance of intoxication from fescue consumption.  
Alkaloids absorbed from the rumen and across the epithelium of the small 
intestine enter the blood stream, where they are quickly removed from circulation by the 
liver and eliminated from the body. Research into the rate of clearance of these 
compounds for livestock has been limited, but it has been demonstrated in sheep that 
ergovaline injected intravenously disappeared from the blood within 1 hour of 
administration (Jaussaud et al., 1998). It should also be noted that lysergic acid in 
particular, begins to appear in the urine of steers that have been moved from E- fescue 
pasture to E+ pasture within 24 hours, demonstrating the speed of alkaloid metabolism 
and elimination in ruminants (Stuedemann et al., 1998). Pharmacokinetic studies 
conducted in nonruminant species using bromocriptine have found that extensive first-
pass biotransformation of this peptide occurred in the liver (Oliver, 1997). The liver 
possibly provides additional alteration and degradation of ergot alkaloids in ruminants 
but there is little information concerning that route of metabolism in livestock available. 
In light of this, it is assumed that biotransformation of ergot alkaloids in ruminants is 
similar to that reported in laboratory species and humans. 
Primary oxidation of a wide variety of steroids, fatty acids, and prostaglandins, as 
well as drugs and environmental pollutants in the liver is catalyzed by the superfamily of 
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cytochrome P450 enzymes (Peyronneau et al., 1994). In humans, biotransformation of 
ergot alkaloids is generally mediated by the CYP3A subfamily of cytochrome P450, 
which consists of 3 genes: CYP3A4, CYP3A5, and CYP3A7 (Ball et al., 1992). CYP3A4 
is the predominant P450 enzyme in the human liver and intestine and has a very active 
role in the metabolism of drugs and toxicants (Strickland et al., 2011). The ergopeptines, 
bromocriptine, ergocryptine, and dihydroergotamine, were found to strongly interact with 
rat liver microsomes by Peyronneau et al. (1994), as a result of the ergopeptines binding 
to a protein site close to the heme. They also demonstrated that the tripeptide portion of 
ergopeptines was essential for these alkaloids to be recognized and bound to CYP3A, and 
alkaloids that lack the moiety, such as lysergic acid derivatives, failed to bind with 
CYP3A. Ergotamine has been shown to undergo enzymatic modification by CYP3A in 
cattle microsomes as well, being converted to more hydrophilic metabolites called M1 
and M2 (8-hydroxy derivatives), which then undergo a second hydroxylation to become 
M3 and M4 (8, 9-dihydroxy derivatives) (Moubarak and Rosenkrans, 2000). Little is 
known about these resulting metabolites, their effects on the body or the role they play in 
fescue toxicosis. Further research is needed to illuminate the process undergone by ergot 
alkaloids once they reach the liver.  
Downstream Effects on Receptors 
As previously mentioned, consumption of endophyte infected tall fescue and 
subsequent liberation of ergot alkaloids into an animal’s gastrointestinal tract can cause a 
variety of physical effects down the line, such as fescue foot, summer slump, and fat 
necrosis. These diverse biological effects are directly related to the structural similarities 
between the tetracyclic ergoline ring of ergot alkaloids and the biogenic amine 
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neurotransmitters norepinephrine, dopamine, and serotonin (Berde and Stürmer, 1978). 
The biogenic amides are associated with transmembrane G protein-coupled receptors 
which are located throughout the body in varying populations depending on tissue type 
(Klotz, 2015). As ligands, ergot alkaloids can stimulate these receptors by acting as 
agonists or partial agonists or they can stifle them by acting as antagonists (Pertz and 
Eich, 1999). To add to the complexity of the issue, serotoninergic, dopaminergic and 
adrenergic receptors are not homogenous. At least 14 distinct subtypes of serotonin 
receptors, 5 subtypes of dopamine receptors, and at least 10 subtypes of adrenoceptors 
have been identified based on structural, transductional, operational, and functional 
differences (Pertz and Eich, 1999). Additionally, slight structural differences between 
alkaloids can vary their specificity to receptor systems and selectivity among the various 
subtypes (Klotz et al., 2010; Choudhary et al., 1995). The non-competitive antagonism 
created by ergot alkaloids binding to these receptors prevents them from performing 
correctly. Persistent binding of alkaloids results in receptor desensitization from 
prolonged stimulation, in turn prompting reduced signal transduction (Millan et al., 
2008). Moreover, agonist occupancy has been shown to enhance the rate of receptor 
internalization (Tan et al., 2004) and excessive binding creates an opportunity for 
alkaloids to accumulate in tissues, which may be released during tissue turnover (Klotz, 
2015). Continuous consumption of toxic fescue and sustained exposure to ergot alkaloids 
can have huge repercussions on biological processes if the rate of alkaloid accumulation 
on receptors exceeds the rate of receptor turnover. Animals exposed to ergot alkaloids 
exhibit a diverse and variable set of symptoms which depend on the type and location of 
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the receptors affected, the quantity and structure of the alkaloid, and any environmental 
stressors that accompany consumption. 
Serotonin Receptors 
Serotonin or 5-hydroxytryptamine (5-HT) receptors are located throughout the 
mammalian body in the central and peripheral nervous system, particularly in blood 
vessels, the gastrointestinal tract and on platelets (Oliver, 1997). They are responsible for 
modulating the release of many neurotransmitters and hormones, which influence 
biological processes like aggression, appetite, mood, nausea and thermoregulation. The 
first demonstration of ergot alkaloids directly acting on 5-HT receptors in bovine 
vasculature was from Dyer (1993), who exposed bovine uterine and umbilical arteries to 
ergovaline, and showed the alkaloid elicited a contraction of both arteries. Additionally, 
they significantly antagonized contractions to ergovaline using ketanserin, a 5-HT2 
receptor antagonist, confirming the contraction of vascular smooth muscle was associated 
with activation of 5-HT2. Later reports showed that the response of lateral saphenous 
veins to 5-HT2A and 5-HT7 agonists were altered in cattle that grazed endophyte infected 
tall fescue (Klotz et al., 2012). A series of in vitro studies investigated the constrictive 
potency of selected ergot alkaloids. They found that ergovaline was the most potent 
alkaloid, followed by ergotamine with a very similar contractile dose response curve to 
ergovaline, then intermediate responses from ergocryptine, ergocristine, ergocornine, and 
ergonovine, and lastly the least potent was lysergic acid (Klotz et al., 2006; 2007; 2008; 
2010). 5-HT2 receptors have also been found in lung tissue and have been shown to be 
involved with pulmonary vasoconstriction and bronchoconstriction in cattle (Oliver, 
1997). This may help explain the pronounced breathing difficulties experienced by cattle 
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on E+ pasture, especially during the summer when animals are exposed to high heat 
situations. While vasoconstriction has been the focus for much of the serotonergic 
receptor research, the effects of ergot alkaloids on the variety of 5-HT receptors in the 
body have not been fully examined. Increased serotonin is known to suppress appetite by 
acting on the hypothalamic satiety center (Rossi-Fanelli and Cangiano, 1991), and it is 
involved in the regulation of gastrointestinal motility (Talley, 1992). These are possible 
routes for ergot alkaloids to reduce feed intake and negatively affect motility and passage 
rate.  
Adrenergic Receptors 
Adrenergic receptors are located on blood vessels throughout the body and 
generally stimulate the sympathetic nervous system, which is responsible for the fight-or-
flight response. When these receptors are triggered, heart rate and blood pressure 
increase, and blood flow is diverted from non-essential organs to skeletal muscle. Cattle 
receiving endophyte-infected fescue hay or seed have shown large variations in plasma 
concentrations of norepinephrine and epinephrine, which resulted in nervous and highly 
excitable animals (Schmidt et al., 1982). Disruption of adrenergic receptors occurs 
quickly after consumption of endophyte infected fescue and causes persistent 
vasoconstriction and dysfunction of blood vessels in the extremities. Heifers showed 
reduced blood flow and narrowing of the lumen of the caudal artery just four hours after 
eating E+ fescue (Aiken et al., 2007). This can result in thickening and damage to the 
vessel’s endothelial lining, as well as edema and thrombosis (Vuong and Berry, 2002). 
Tissue necrosis or dry gangrene is a direct result and a severe consequence of endophyte 
consumption.  
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There are two groups of adrenoreceptors, α (subtypes: α1 and α2) and β (subtypes: 
β1, β2, and β3). There is no evidence that ergot alkaloids either stimulate or block β 
adrenoreceptors (Salzmann and Bucher, 1978). Both α1 and α2 adrenergic receptors have 
been found on the dorsal pedal vein of cattle (Solomons et al., 1989). Lateral saphenous 
veins from cattle grazing E+ and E- pastures showed no difference in contractile response 
when exposed to phenylephrine, an α1 receptor agonist, proving α1 receptors are not 
affected by ergot alkaloid consumption. Conversely, when veins from E+ animals were 
exposed to BHT-920, an α2 receptor agonist, they had enhanced reactivity and greater 
contractile response, demonstrating that the agonist effect of many ergot alkaloids is 
greater on α2 receptors (Oliver et al., 1998). E+ fescue consumption has been found to 
decrease blood flow to core and peripheral tissues, including rib and leg skin, adrenal 
glands, cerebellum, duodenum, and colon (Rhodes et al., 1991).  These types of changes 
were expected to be accompanied by increased blood flow to other areas but the blood 
flow to other tissues remained unchanged. This led to the conclusion that E+ fescue 
reduced the cardiac output in cattle (Rhodes et al., 1991). During continuous heat 
challenge, animals consuming E+ fescue experienced a shift in core body temperature 
from 38.8°C to 39.2°C; this was accompanied by increases in respiration rate, respiratory 
vaporization, skin vaporization, and skin temperature but not a significant change in heat 
production (Al-Haidary et al., 2001). Researchers believe that vasoconstriction mediated 
by α-adrenergic receptors in subcutaneous areas reduces evaporative heat loss from the 
skin in heat stress situations, thus causing the increased core temperature seen in cattle 
afflicted with fescue toxicosis. α2 receptors are also present on blood platelets, and when 
they are stimulated by ergot alkaloids platelet production of thromboxane increases, 
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which in turn induces platelet aggregation and arterial constriction (Oliver, 1997). This 
combined with bronchial constriction caused by alkaloid influence on serotonergic 
receptors, results in reduced blood O2 saturation and tissue oxygenation. This can explain 
the increased respiration rate seen by Al-Haidary et al. (2001). 
Dopamine Receptors 
The five subtypes of dopamine receptors are divided into D1-like (D1 and D5) 
and D2-like (D2, D3, and D4) subfamilies. D1 and D2 receptor subtypes are located in 
the neostriatum of the brain, where dopamine is important for motor function. D2 
receptors are also found at high levels in the pituitary gland. D3 receptors are in the 
limbic regions of the brain, where they control aspects of behavior, emotion, motivation, 
and cognition. D4 receptors are sometimes found in the brain but are more common in 
the cardiovascular system (Pertz and Eich, 1999). Ergot alkaloids are agonistic to D2 
receptors, which results in a significant reduction in both circulating and releasable 
prolactin from the anterior pituitary, a classic indication of fescue toxicosis (Schillo et al., 
1988). Prolactin is essential for regulating metabolism, the immune system, and 
pancreatic development, as well as regulating milk synthesis and secretion. Decreased 
milk production in cows and ewes, and agalactia in mares grazing E+ pasture is a result 
of the decline in circulating prolactin (Freeman et al., 2000). At the onset of spring, 
longer days typically elevate prolactin levels to initiate shedding of the winter hair coat, 
but animals suffering from ergot alkaloid poisoning have prolactin levels that are too low 
to trigger shedding. These animals will maintain a shaggy coat, even in the heat of 
summer, which further exacerbates heat stress and elevates core body temperature 
triggered by alkaloid-induced vasoconstriction (Aiken et al., 2011). Researchers have 
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suggested that decreased prolactin levels are also involved in the reduced reproduction 
seen in seasonal breeding livestock species grazing E+ fescue pastures (Strickland et al., 
2011). Intravenous administration of ergotamine to cattle has resulted in decreased 
plasma insulin concentrations and increased glucagon within 1 hour of dosing (Browning 
et al., 2000). The exact mechanism for these effects is still unknown. It has been shown 
that D2 receptors may be involved in pancreatic function and associated insulin 
regulation (Liang et al., 1998). Disruption of these dopamine receptors by agonists has 
resulted in decreased insulin response and glucose intolerance (García-Tornadú et al., 
2010). More research in this area could provide the mechanism by which ergot alkaloids 
affect insulin secretion in cattle. 
Solutions for Fescue Toxicosis 
Consumption of endophyte infected tall fescue results in a multitude of 
physiological disruptions in livestock, leading to major losses in weight gains for stocker 
animals, which limits the usefulness of fescue pastures for producers. Several pasture 
management strategies have been developed to regulate alkaloid load and animal 
performance while grazing tall fescue. These methods include increasing biodiversity and 
favoring other grass species, removing infected tall fescue and replacing it with nontoxic 
endophyte cultivars, clipping seed heads before grazing, moving cattle off toxic fescue 
pastures during the summer, and feeding concentrates to improve weight gains during 
hotter months (Strickland et al., 2011; Aiken et al., 2006). Another approach to improve 
cattle performance is the use of steroidal implants, which have been shown to increase 
daily gains in animals grazing infected pasture (Brazle and Coffey, 1991; Beconi et al., 
33 
 
1995; Aiken et al., 2006; Carter et al., 2010). These implants have been used for decades 
to enhance feed efficiency, rate of gain, and muscle gain in feedlot cattle.  
Estrogenic and androgenic steroids are strong growth promoters through 
stimulation of growth hormone and IGF-1 secretion. Estradiol acts directly upon skeletal 
muscle through estrogen receptors (ER) as well as indirectly through stimulation of 
growth hormone secretion, GH-receptors in the liver, and IGF-1 secretion into the blood 
(Meyer, 2001; Dayton and White, 2014). Steers treated for as few as 7 days with a 
combined TBA and estradiol implant have shown increased IGF-1 mRNA levels in 
longissimus muscle compared to nonimplanted steers (Pampusch et al., 2008; Johnson et 
al. 1998b, White et al., 2003). The exact mechanism for implant-stimulated growth in 
beef cattle is uncertain, but studies indicate their effect on muscle satellite cells may play 
an important role (Johnson et al., 1998a; Kamanga-Sollo et al., 2008b; Pampusch et al., 
2008).  
Since the number of muscle fibers in cattle is fixed at birth, postnatal muscle 
growth results from hypertrophy of existing muscle fibers, this in turn requires an 
increase in myogenic satellite cells which fuse to the periphery of the muscle fiber (Moss 
and Leblond, 1971). Muscle samples taken from steers implanted with a combined 
trenbolone acetate and estradiol implant contained a higher number of satellite cells than 
samples taken from nonimplanted steers, suggesting that having increased numbers of 
satellite cells available to fuse with muscle fibers contributes significantly to steroid-
induced muscle growth in meat-producing animals (Johnson et al., 1998a). Local 
production of IGF-1 in skeletal muscle is thought to play a role in supporting normal 
muscle growth and may be partially responsible for the increased number of satellite 
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cells, increased hypertrophy and increased muscle growth seen in animals treated with 
steroidal implants (Kamanga-Sollo et al., 2008). IGF-1 is also an important stimulator of 
the mTOR pathway, which is responsible for protein synthesis and muscle gain in 
growing animals (Yoon, 2017). 
While research has shown that implants are a useful tool for producers that graze 
stocker cattle on tall fescue, none have investigated the effects of implantation on protein 
synthesis pathways in the muscle of cattle or how ergot alkaloids can interfere with these 
pathways. Intraperitoneal injections of ergot alkaloids in rats have been shown to inhibit 
the growth hormone axis (Flückiger et al., 1978) and structurally similar chemicals 
(indoles) have been shown to inhibit the mTOR pathway in cancer cells (Ahmad et al., 
2013). It has also been demonstrated that cattle grazing endophyte-infected pastures not 
only had lower rates of gain compared to controls, but also exhibited a slight decrease in 
IGF-1 responsiveness to estradiol-17β (Davenport et al., 1993). It is currently unknown if 
ergot alkaloids can affect protein synthesis and the mTOR pathway or if these negative 
effects are alleviated by implantation with anabolic agents. 
Introduction to mTOR 
Eukaryotic cells use the mechanistic target of rapamycin (mTOR) signaling 
pathway to respond to environmental cues, such as growth factors and nutrients, as well 
as cellular energy levels and stress. This allows cells to regulate growth, metabolism, and 
maintain homeostasis in changing conditions. The mTOR pathway (Figure 2.2) occupies 
a central role in regulating protein synthesis, autophagy, and many other essential cell 
processes. Disruption of these processes caused by deregulated mTOR signaling, has 
been implicated in cancer, diabetes, and neurodegeneration (Saxton and Sabatini, 2017). 
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Development of targeted therapies to control these conditions and reverse mTOR 
disruption is a major focus of future research concerning the mTOR pathway. 
The study of mTOR began with a Canadian expedition to the South Pacific Island 
of Rapa Nui (also known as Easter Island) in 1964. Scientists on this expedition hoped to 
identify natural products from plants and soil on the island that had therapeutic 
properties. In 1972, Suren Sehgal isolated a compound from the bacterium Streptomyces 
hygroscopicus, which was present in soil samples taken from the island. He reported that 
it possessed potent antifungal activity and named it rapamycin (Vézina et al., 1975). 
Other strains of S. hygroscopicus have also been used to produce several medically 
important chemical compounds and enzymes, including the anthelmintic milbemycin (a 
precursor of moxidectin), anti-cancer drugs - called indolocarbazoles, and numerous 
antibiotics. Further testing revealed that rapamycin also had immunosuppressive and 
cytostatic anti-cancer activity.  
The target of rapamycin (TOR) protein was originally discovered in yeast in 1991 
by Joe Heitman, Rao Movva, and Mike Hall, by using genetic screens for rapamycin 
resistance. Through this method, they were able to identify three target proteins for 
rapamycin. The first being the small FKBP12 protein, which serves as a cellular receptor 
for the drug, and together they form the FKBP12-rapamycin complex (Heitman et al., 
1991). Mutants without FKBP12 were viable and completely resistant to rapamycin, 
proving that the protein was essential. They also uncovered the TOR1 and TOR2 
proteins, which were demonstrated to be directly targeted by the FKBP12-rapamycin 
complex, hence the name - target of rapamycin (Heitman et al., 1991). A few years later, 
several groups described the direct target of the FKBP12-rapamycin complex in 
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mammals and sequence analysis found it to be a homolog of yeast TOR genes (Saxton 
and Sabatini, 2017). This protein was named the mechanistic (formerly “mammalian”) 
target of rapamycin, or mTOR. 
The mTOR protein is a 298 kDa serine/threonine protein kinase that belongs to 
the PI3K-related kinase (PIKK) family; it forms the catalytic subunit of the protein 
complexes mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) (Saxton 
and Sabatini, 2017). mTORC1 has five components: mTOR, Raptor (regulatory protein 
associated with mTOR), mLST8 (mammalian lethal with Sec13 protein 8), PRAS40 
(proline rich Akt substrate of 40 kDa), and DEPTOR (DEP domain containing mTOR 
interacting protein). Raptor and mLST8 promote mTOR function. Raptor is responsible 
for recruiting substrate to mTORC1 and keeping the complex correctly localized within 
the cell (Nojima et al., 2003), while mLST8 associates with the catalytic domain and may 
provide stabilization of the kinase activation loop (Yang et al., 2013). PRAS40 and 
DEPTOR inhibit mTOR function, possibly by directly inhibiting substrate binding 
(Laplante and Sabatini, 2009). mTORC2 has six components: mTOR, Rictor (rapamycin 
insensitive companion of mTOR), mSIN1 (mammalian stress-activated protein kinase 
interacting protein), Proctor1/2, DEPTOR, and mLST8. DEPTOR and mLST8 are 
believed to be the same in both complexes, Rictor likely has a similar function to Raptor, 
and mSIN1 and Proctor1/2 are considered regulatory subunits. The FKBP12-rapamycin 
complex directly inhibits mTORC1, but mTORC2 is notably insensitive to short term 
treatment. Long term exposure will eventually terminate mTORC2 signaling, not by 
directly inhibiting or binding to mTORC2, but likely by binding to solitary mTOR, 
preventing its incorporation into new mTORC2 complexes (Lamming et al., 2012).  
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Upstream of mTORC1 
Activation of mTORC1 (Figure 2.2) should only occur after feeding, when 
sufficient energy and chemical building blocks are present, making increased anabolism 
possible. Through endocrine and other chemical signals, mTORC1 stimulates growth and 
energy storage in tissues, such as the liver and skeletal muscle, but is inhibited when 
resources are limited during fasting (Saxton and Sabatini, 2017). Mechanisms for 
upstream signaling of mTORC1 include growth factors, amino acids, energy status, 
oxygen levels, and DNA damage. An important regulator of mTORC1 activity is the 
heterotrimeric complex TSC (tuberous sclerosis complex), comprised of TSC1, TSC2, 
and TBC1D7 (Dibble et al., 2012). The complex functions as a GTPase-activating protein 
(GAP) for the GTP-binding protein Rheb (Ras homolog enriched in brain), which 
directly stimulates mTORC1 activity when activated (Sancak et al., 2007). TSC 
downregulates mTORC1 by converting Rheb to its inactive, GDP-bound state. Excessive 
inactivation of TSC1/2 is linked with the presence of numerous benign tumors, composed 
of disorganized and enlarged cells; this disease is known as tuberous sclerosis. 
Growth Factors 
Multiple growth factor pathways cause phosphorylation and inactivation of TSC. 
The insulin/insulin-like growth factor (IGF) pathway does so through multisite 
phosphorylation from protein kinase B/Akt, which causes TSC2 to dissociate from the 
lysosomal membrane and limits its contact with Rheb (Menon et al., 2014). This pathway 
is activated when insulin binds to receptors on the cell surface; this promotes the tyrosine 
kinase activity of the insulin receptor, the recruitment of IRS1 (insulin receptor substrate 
1), the activation of PI3K (phosphoinositide 3-kinase), the production of PtdIns(3,4,5)P3, 
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and the recruitment and activation of Akt at the plasma membrane. Receptor tyrosine 
kinase-dependent Ras signaling also acts on TSC2 through the MAP kinase, ERK1/2 
(extracellular regulated kinase 1/2) and its effector, p90RSK1 (ribosomal S6 kinase 1), 
but it’s unclear how this pathway inhibits GAP activity (Laplante and Sabatini, 2009). 
Exactly how these signals are coordinated by the TSC complex and their corresponding 
impact on mTORC1 in different situations has not been fully illustrated. 
Energy Status and Oxygen Levels 
 Intracellular and extracellular stresses, such as low ATP levels and hypoxia, also 
elicit a response from mTORC1. When glucose is scarce, cellular energy is reduced (low 
ATP:ADP ratio) and the stress responsive regulator AMPK (AMP-activated protein 
kinase) is activated. Activated AMPK can directly inhibit mTORC1 by phosphorylating 
Raptor or indirectly inhibit it by phosphorylating and activating TSC2, which results in 
the previously mentioned downstream effects (Saxton and Sabatini, 2017). It has been 
suggested that mTORC1 can sense glucose deprivation through other mechanisms as 
well, because cells lacking AMPK still show mTOR pathway inhibition, through 
inhibition of the Rag GTPases (Kalender, et al., 2010). Oxygen deprivation also affects 
mTORC1 activity through multiple pathways. During mild hypoxia, ATP levels are 
reduced, which activates AMPK and inhibits mTORC1 in the same manner as glucose 
deprivation. This state also activates TSC2 through the induction of REDD1 (Regulated 
in DNA damage and development 1) (Brugarolas et al., 2004). In situations where growth 
factors are present, but oxygen levels are low, REDD1 disrupts the interaction between 
TSC2 and inhibitory 14-3-3 proteins, freeing TSC2 to then inhibit mTORC1 activity 
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because oxygen levels are not high enough to generate the cellular energy necessary for 
the pathway (DeYoung et al., 2008). 
Amino Acids 
 Dietary amino acids play a vital role in protein synthesis by strongly stimulating 
the mTOR pathway, as well as providing energy and carbon for other metabolic 
processes. Recent advancements have shown that mTORC1 activation by amino acids is 
a complex pathway, tightly coupled to dietary amino acid concentrations, and 
independent of TSC1/2. Lysosomes are now considered active participants in the process 
of sensing amino acids in the cell, and mTORC1 uses them as a platform for activation. 
Rag GTPase proteins attached to the lysosomal membrane are stimulated by intercellular 
amino acids, which converts them to their active nucleotide-bound state, so they can bind 
to Raptor and move mTORC1 to the lysosomal surface, where Rheb is located. This 
relies on Rheb not being inactivated by the TSC1/2 complex, ensuring that mTORC1 is 
activated only when both nutrient and growth factor conditions are suitable. 
Regulating mTORC1 through nutrients occupies a significant amount of protein 
space in the cell; so far 26 proteins have been identified in the nutrient sensing arm of the 
pathway and mutations of these proteins cause the mTORC1 hyperactivation seen in 
cancer and neurological diseases (Sabatini, 2017). Many multiprotein complexes respond 
to nutrients and regulate the nucleotide state of Rag GTPase proteins, which are the 
keystone of lysosomal and cytosolic amino acid sensing for mTORC1. SLC38A9 is an 
important regulator and is required for lysosomal arginine to activate mTORC1; it is also 
responsible for transporting amino acids and signaling their presence (Jung et al., 2015). 
The cytosolic signaling pathway to mTORC1 contains the key protein complexes 
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GATOR1 and GATOR2. GATOR1 is tethered to the surface of lysosomes by the 
KICSTOR complex and has an inhibitory effect on mTORC1 by acting as a GAP for 
RagA/B. GATOR2 interacts with the tethered GATOR1 and is a positive regulator of 
mTORC1 signaling (Bar-Peled et al., 2013). Sestrin2 is a direct leucine sensor that 
interacts with GATOR2 and works to inhibit it in the absence of leucine. When leucine is 
available and binds to Sestrin2, it dissociates from GATOR2, allowing it to block 
GATOR1’s inhibitory effects on mTORC1 (Saxton and Sabatini, 2017). CASTOR1 
(Cellular Arginine Sensor for mTORC1) acts on GATOR2 in a similar way, except it 
inhibits mTORC1 in the absence of arginine. Additional Rag-dependent and independent 
nutrient sensing pathways have also been described, namely those involving methionine 
and glutamine. How the mTORC1 pathway detects other nutrients has yet to be 
discovered. 
Upstream of mTORC2 
Unlike mTORC1, relatively little was known about the upstream signaling and 
cellular functions of mTOR Complex 2 until recently, and there is still much to be 
discovered. While it is insensitive to nutrients, growth factors such as insulin, insulin like 
growth factor (IGF), and hormones stimulate mTORC2 signaling through PI3K, using a 
signaling mechanism distinct from the pathways that activate mTORC1. The subunit 
mSIN1 in the mTORC2 complex is essential for insulin-dependent regulation of 
mTORC2 because it contains a phosphoinositide-binding PH domain. In the absence of 
insulin, this domain inhibits mTORC2 catalytic activity. Signaling by PI3K stimulates 
mTORC2 to associate with ribosomes, which in turn, serve as a scaffold to allow 
mTORC2 to phosphorylate substrates and ensure mTORC2 is in the proper location (Oh 
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and Jacinto, 2011). The mSIN1 subunit can be phosphorylated by Akt, which creates a 
positive-feedback loop, as partial activation of Akt encourages activation of mTORC2, 
which then phosphorylates and fully activates Akt (Yang et al., 2015) 
Due to a negative feedback loop between mTORC1 and insulin/PI3K signaling, 
mTORC2 can also be regulated by mTORC1. This occurs when mTORC1 
phosphorylates and activates Grb10 (growth factor receptor-bound protein 10), which 
negatively regulates insulin/IGF-1 receptor signaling upstream of mTORC2 and Akt (Yu 
et al., 2011). S6K1, a substrate of mTORC1, also stifles mTORC2 activation by 
degrading IRS1, this is further discussed in the following section. 
Downstream of mTORC1 
After upstream activation of the mTOR Complex 1 occurs, there are a multitude 
of downstream pathways that the complex controls in order to maintain cellular balance 
in response to environmental conditions. mTORC1 positively regulates anabolic 
processes necessary for growth and division, such as biosynthesis of proteins, lipids, and 
organelles, by limiting catabolic processes like autophagy (Saxton and Sabatini, 2017). 
Protein Synthesis 
Initiation of protein synthesis promotes ribosome biogenesis and mRNA 
translation; it is predominantly controlled through two key proteins that are directly 
phosphorylated by mTORC1, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eIF4E 
binding protein 1). S6K1 is phosphorylated on its hydrophobic motif site, Thr389, 
allowing further phosphorylation and activation by the enzyme PDK1 (3-
phosphoinositide-dependent protein kinase-1). Once this occurs, S6K1 can then 
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phosphorylate and regulate several downstream substrates such as eIF4B (eukaryotic 
translation initiation factor 4B), which is a positive regulator of the 5′cap binding eIF4F 
complex, as well as eEF2K (eukaryotic elongation factor 2 kinase), and ribosomal protein 
S6, both of which subsequently promote translation initiation and elongation (Mao and 
Zhang, 2018; Saxton and Sabatini, 2017). PDCD4 (programmed cell death protein 4), a 
protein known to bind eIF4A, inhibit translation initiation, and act as a tumor suppressor, 
is also phosphorylated by S6K1, which promotes degradation of the protein and stops 
inhibition (Dorrello et al., 2006). Interaction between S6K1 and the enzyme SKAR 
(S6K1 Aly/REF-like substrate) increases the translation efficiency of spliced mRNA (Ma 
et al., 2008). S6K1 can also modify the level of input from growth factors, such as insulin 
and IGF-1 as part of an auto-regulatory pathway, called the S6K1-dependent negative 
feedback loop. Activated S6K1 directly phosphorylates and destabilizes IRS1, hindering 
its ability to associate with the insulin receptor, and desensitizing tissues to insulin 
(Manning, 2004). An increase in IRS1 phosphorylation suppresses mTORC2 activation 
and reduces Akt activity, which further affects downstream deactivation of TSC and 
FoxO, leading to inhibition of mTORC1 and disruption of mTORC2 activity, 
respectively. This regulatory pathway is of utmost importance when studying metabolic 
disorders characterized by insulin resistance, such as type 2 diabetes, where excess amino 
acid consumption and high fat diets cause mTORC1 to be chronically activated, and 
S6K1 to constantly shut down insulin response in certain cells (Manning, 2004). 
 The other downstream substrate of mTORC1 is 4E-BP1, the action of this protein 
is not related to S6K1. 4E-BP1 is responsible for inhibiting translation by binding eIF4E 
(eukaryotic translation initiation factor 4E) and preventing the assembly of the eIF4F 
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complex. The complex assembly is necessary for recruiting 40S ribosomal subunits to the 
5’ end of mRNA. Multiple phosphorylations by mTORC1 cause 4E-BP1 to dissociate 
from eIF4E, allowing mRNA translation to occur (Saxton and Sabatini, 2017).   
Lipid and Glucose Metabolism 
Lipids are essential for construction of new membranes and cell expansion. De 
novo lipid synthesis in the cell is promoted by mTORC1 through SREBPs (sterol 
responsive element binding protein). These transcription factors control the expression of 
genes responsible for fatty acid and cholesterol biosynthesis. In the inactive state, 
SREBPs are attached to the membranes of the nuclear envelope and endoplasmic 
reticulum. When sterol levels are low in a cell, SREBPs are cleaved and translocated to 
the nucleus, where they bind to specific DNA sequences and upregulate the synthesis of 
sterol synthesizing enzymes. High sterol levels inhibit SREBP cleavage and reduce 
synthesis through a negative feedback loop. SREBP can also be activated independently 
by mTORC1 through S6K1, which mediates activation of transcription factors (Düvel et 
al., 2010). Another substrate, Lipin1, is an inhibitor of SREBP, but can be 
phosphorylated and inactivated by mTORC1, positively affecting SRBEP activity 
(Peterson et al, 2011). Activation of SREBP in this manner leads to increased flux 
through the oxidative pentose phosphate pathway, which uses carbons from glucose to 
generate NADPH and other metabolites needed for growth and proliferation. mTORC1 
also encourages a shift in glucose metabolism from oxidative phosphorylation to 
glycolysis, this promotes growth through the incorporation of nutrients into new biomass. 
The shift occurs because mTORC1 activation stimulates increased translation of the 
transcription factor HIF1α (hypoxia-inducible factor-1α), which in turn facilitates the 
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expression of several glycolytic enzymes such as PFK (phospho-fructo kinase) (Düvel et 
al., 2010).  
Regulation of Protein Turnover 
 The mTORC1 pathway also works to suppress protein catabolism, particularly 
autophagy, as another method for promoting cell growth. An early autophagic step is the 
formation of autophagosomes, driven by the activation of the kinase ULK1, which forms 
a complex with ATG13, FIP2000, and ATG101. When sufficient nutrients are available, 
mTORC1 is active and phosphorylates ULK1, preventing its activation by AMPK, a key 
promoter of autophagy (Kim et al., 2011). Regulation of autophagy also occurs when 
mTORC1 phosphorylates and inhibits the nuclear translocation of TFEB, a transcription 
factor that promotes the expression of genes for lysosomal biogenesis and autophagic 
machinery (Saxton and Sabatini, 2017). 
 Protein turnover is also controlled by the ubiquitin-proteasome system (UPS). The 
UPS is a major intercellular protein degradation system that selectively targets proteins 
for 20S proteasome degradation by covalent modification with ubiquitin. Contradicting 
results from recent studies have demonstrated that the exact mechanism used by 
mTORC1 to regulate UPS has yet to be defined. Two studies found that acute mTORC1 
inhibition expediates proteasome-dependent proteolysis, either by an increase in protein 
ubiquitylation or an increased number of proteasomal chaperones, through inhibition of 
Erk5 (Rousseau and Bertolotti, 2016; Zhao et al., 2015). Yet a study done a couple years 
earlier, demonstrated that genetic hyper-activation of mTORC1 elevated expression of 
proteasome subunits and increased proteasome activity (Zhang et al., 2014). Further 
research is needed to illuminate the regulation of this system, but it is possible that acute 
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mTORC1 inhibition promotes proteolysis to restore free amino acid pools, while chronic 
mTORC1 activation drives an increase in protein turnover to compensate for an increase 
in protein synthesis (Saxton and Sabatini, 2017). 
Downstream of mTORC2 
 While some aspects of mTORC2 signaling remain elusive, it has been identified 
as a key regulator in various cellular processes such as cell survival, anabolism, 
proliferation, and cytoskeleton organization. mTORC2 phosphorylates several protein 
kinases from the AGC family, including Akt, SGK, PKA, PKG, and PKC. These include 
enzymes that regulate the actin cytoskeleton (PKCα), and various aspects of cytoskeletal 
remodeling and cell migration (PKCδ, PKCζ, PKCγ, and PKCε) (Saxton and Sabatini, 
2017). It could be said that the most important role of mTORC2 is the phosphorylation 
and activation of Akt. Identifying Akt as a substrate of mTORC2 linked the mTORC2 
protein to glucose homeostasis, diabetes, adipogenesis, and cancer. Full activation of Akt 
requires phosphorylation by PDK1 at Ser308 and mTORC2 at Ser473, respectively 
(Sarbassov et al., 2005). Active Akt promotes cell survival, proliferation, and growth by 
phosphorylating and inhibiting several substrates. These include the metabolic regulator 
GSK3β, the mTORC1 inhibitor TSC2, and the transcription factors FoxO1 (forkhead box 
protein O1) and FoxO3a, which control gene expression for stress resistance, metabolism, 
cell-cycle arrest and apoptosis (Laplante and Sabatini, 2009).  
Physiological Roles of mTOR 
 Multicellular organisms face constant changes in energy availability because of 
periods of fasting or feeding. This pushed for the evolution of the ability to adjust whole 
body metabolism in order to maintain homeostasis and survivability. During periods of 
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fasting, available nutrients and circulating growth factors decline, requiring induction of a 
catabolic state to mobilize energy stores and maintain crucial body functions. 
Alternatively, during the fed-state there is an abundance of available nutrients, which 
requires a switch to anabolic growth and energy storage. Metabolic regulation in the 
organism relies on mTOR signaling to coordinate anabolic and catabolic processes, just 
as it does at the cellular level. Proper modulation of the mTOR pathway is necessary to 
avoid negative physiological outcomes and a variety of disease states are associated with 
poorly regulated mTOR, which prevent organisms from responding to changing 
environments. 
Glucose Homeostasis  
 When an animal’s blood glucose drops, the liver responds by promoting 
autophagy, gluconeogenesis, and the use of other energy sources such as ketone bodies. 
There is evidence suggesting the liver’s response to dietary changes is dependent on 
regulation of mTORC1 signaling, and disruption of the pathway will also disrupt proper 
liver function. Mice lacking liver TSC1, a crucial down-regulator of mTORC1, suffer 
from perpetually activated mTORC1 signaling, which in turn suppresses the master 
transcriptional activator of ketogenic genes, PPARα (peroxisome proliferator activated 
receptor α), so the animal fails to generate ketone bodies (Sengupta et al., 2010). 
Autophagy in the liver during fasting is essential for supplying free amino acids for 
gluconeogenesis. Sustained mTORC1 activity during this period has been shown to 
prevent autophagy in the liver of mice, resulting in fatal hypoglycemia when fasted 
(Efeyan et al., 2013). Conversely, when blood glucose rises following a meal, and insulin 
is released from β-cells in the pancreas, hepatic mTORC2 typically stimulates glucose 
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metabolism via Akt signaling. Mice lacking Rictor in the liver - thus lacking sufficient 
mTORC2 expression and subsequent Akt phosphorylation - have impaired glycolysis and 
lipogenesis (Mao and Zhang, 2018). Additionally, deletion of hepatic Sestrin3, an 
upstream regulator of mTORC2 similar to Sestrin2, results in insulin resistance and 
glucose intolerance 
 Regulation of pancreatic β-cell development and function can also be affected by 
improper mTORC1 signaling. Mice without mTOR or Raptor in β-cells or pancreatic 
progenitor cells have reduced beta cell mass, abnormal postnatal islet development, 
hypoinsulinemia, and glucose intolerance (Mao and Zhang, 2018). Mice lacking β-cell 
TSC2 exhibit hyperactivation of mTORC1, which has a biphasic effect on β-cell 
function. This means that young TSC2 knock out mice show increased β-cell mass, 
higher insulin levels, and improved glucose tolerance; but the effect is reversed in older 
animals, which gradually lose β-cell mass due to increased apoptosis, in turn triggering 
hyperglycemia (Mori et al., 2009; Shigeyama et al., 2008). This demonstrates that high 
mTORC1 activity in the pancreas is beneficial at first, when β-cells expand in response to 
an increased glycemic load and produce more insulin, but eventually this will lead to 
exhaustion and a rapid decline in β-cell function over time. The progression of diet-
induced (type 2) diabetes is similar to this biphasic effect. Obese or high fat diet treated 
mice show increased mTORC1 signaling in the pancreas and other tissues, likely due to 
increased levels of circulating insulin, amino acids, and proinflammatory cytokines 
(Khamzina et al., 2005), which also contributes to increased feedback inhibition of 
insulin/PI3K/Akt signaling, resulting in peripheral insulin resistance. Unlike mTORC1, 
mTORC2 activity declines in β-cells in the diabetic state. 
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Skeletal Muscle and Whole-Body Metabolism  
 A large portion of the total body lean mass is comprised of skeletal muscle, and 
this organ plays a multi-faceted role in regulating whole-body metabolism. Firstly, it is 
the main organ responsible for insulin-induced glucose uptake. Defects in this process, 
such as insulin resistance, result in the development of type 2 diabetes. Mice lacking 
muscle TSC1 are lean but also develop insulin resistance and glucose intolerance. Even 
when consuming a high fat diet, these mice have reduced glucose uptake in the muscle, 
as well as reduced glycogen and lipid deposition in the liver (Guridi et al., 2016). This 
occurs because these mice do not have the proper controls in place through TSC to 
negatively regulate mTORC1, so the pathway is constantly activated. This results in 
S6K1 activation, which directly phosphorylates IRS1 and causes its degradation. The 
consequence is interrupting PI3K-Akt activation, causing negative downstream effects on 
glucose uptake, glycogen accumulation and lipid deposition. 
 Autophagy in the skeletal muscle is also affected by mTORC1 activity. Constant 
activation of mTORC1 promotes short-term muscle growth, but eventually inhibits the 
body’s ability to induce autophagy in the tissue. Without the ability to turn over old or 
damaged tissue, muscle growth is stunted, resulting in reduced muscle mass and muscle 
fiber size in older animals, leading to myopathy, low body mass, and early death (Castets 
et al, 2013). This suggests that optimal muscle health and function occurs when there are 
alternating high and low periods of mTORC1 activation, like what occurs with typical 
feeding and fasting cycles (Saxton and Sabatini, 2017).  
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Adipogenesis and Lipid Homeostasis  
 Another organ that contains a critical regulatory aspect of the mTOR pathway is 
adipose tissue. Development of obesity and insulin resistance occurs there, and mTOR is 
involved in multiple components of adipose tissue biology, including adipogenesis, 
maintenance of fat tissues, and lipid synthesis in response to feeding and insulin. When 
mice adipocytes do not have functional mTOR, they show reduced tissue mass, insulin 
resistance, and fatty liver, highlighting the important role of mTOR in the adipose and 
systemic energy metabolism (Shan et al., 2016). Deregulation of mTORC1 through 
deletion of TSC2 stimulates adipocyte differentiation but is countered by regulation of 
the translation of PPARγ by 4EBP1. Mice lacking S6K1 or Raptor in adipocytes will 
both remain lean and demonstrate resistance to weight gain on a high fat diet; this is due 
to a hindered ability to generate new adipocytes (Lamming and Sabatini, 2013).  
 Adipogenesis may also be regulated by mTORC1 through the regulation of 
SREBPs. While rapamycin treatment has been shown to impair nuclear accumulation of 
SREBPs, the exact regulatory mechanism is still uncertain, but S6K1 is thought to be 
involved. Another path may be through lipin1. mTORC1 phosphorylates lipin1, causing 
it to remain inactive in the cytoplasm and not move to the nucleus where it represses 
SREBP dependent gene transcription and upregulation of sterol synthesis (Lamming and 
Sabatini, 2013). Additionally, regulation of mTORC1 occurs indirectly through direct 
phosphorylation and mediation of Akt activity by mTORC2 in response to growth 
factors, making it an important facet of the pathway in adipose tissue. Loss of mTORC2 
activity in adipocytes weakens Akt signaling to mTORC1, resulting in defective SREBP 
activation and lipogenesis, and ultimately insulin resistance, which is why mTORC2 
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signaling in adipocytes is of primary importance. Although further research is necessary 
to discern the finite molecular mechanisms of the mTOR pathway in adipose tissue, the 
overall importance of mTORC1 and mTORC2 to adipocyte function and lipid 
metabolism has been demonstrated. 
Conclusion 
The story of tall fescue is tightly woven with that of the endophyte Epichloё 
coenophiala. Modern grazing operations cannot ignore the benefits and drawbacks of the 
relationship. Novel endophyte cultivars have been developed to replace toxic tall fescue, 
but the reality remains, that a majority of pastures in the United States still produce toxic 
ergot alkaloids that cause biological issues for livestock. It is known that because of their 
structural similarities to neurotransmitters, alkaloids can bind to receptors throughout the 
body and cause a variety of physiological issues in livestock. Further investigation into 
the absorption and disposal of ergot alkaloids by the animal’s body as well as their 
impact of on digestion and metabolic pathways are necessary to fully understand this 
disease. The objective of the current study was to determine if fescue-derived alkaloids 
have an inhibitory action on the mTOR pathway and decrease muscle protein synthesis 
by a direct effect on signal proteins. 
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Figure 2.1  Ergot alkaloids produced by endophytic fungi of the genus Epichloë in infected plants  
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Figure 2.2  Signaling pathways contributing to muscle protein synthesis 
This figure is a simplified overview of signaling molecules involved in protein synthesis. An arrow indicates activation, a 
perpendicular line indicates inhibition, and lines marked with a cross indicate that the action of this signaling molecule on its target 
is blocked under anabolic conditions. 
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CHAPTER 3. IMPACT OF ERGOT ALKALOID AND ESTRADIOL 17B ON WHOLE-BODY 
PROTEIN TURNOVER AND EXPRESSION OF MTOR PATHWAY PROTEINS IN MUSCLE OF 
CATTLE 
Introduction 
The mutualistic relationship between the grass Festuca arundinacea and the 
endophyte fungus Epichloё coenophiala creates an exemplary forage for livestock that 
has been planted on millions of acres throughout the United States. The endophyte is 
given nutrition, protection, and an avenue for reproduction, while the plant receives 
advantages in persistence, survivability, and protection against biotic attack (Belesky and 
West, 2009). One of these endophytic protections is the production of ergot alkaloids in 
the tissues of tall fescue. These compounds have been determined to cause the variety of 
symptoms present in animals affected by fescue toxicosis. The most prominent seen in 
cattle consuming endophyte infected fescue are reduced feed intake, lower weight gains, 
respiratory distress, vasoconstriction, and disruption of normal hormone levels 
(Hoveland, 2009). 
Ergot alkaloids contain an ergoline ring structure, which are similar to structures 
present in the neurotransmitters serotonin, dopamine, norepinephrine and epinephrine, 
allowing them to bind to biogenic amine receptors and elicit negative effects (Strickland 
et al, 2011; Berde and Strumer, 1978). These biogenic amines regulate appetite, 
cardiovascular function, endocrine activity, gastrointestinal motility, muscle contraction, 
and thermoregulation in mammals (Berde and Strumer, 1978; Thompson and 
Stuedemann, 1993). The classic indication of fescue toxicosis is a significant reduction in 
circulating prolactin; this results from agonistic action on D2 dopamine receptors by 
ergot alkaloids (Schillo et al., 1988). Prolactin is essential for regulating metabolism, the 
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immune system, milk synthesis, milk secretion, and pancreatic development. Cattle 
suffering from fescue toxicosis have prolactin levels that are too low to trigger seasonal 
shedding; this may also cause seasonal breeding livestock species to have reduced 
reproductive efficiency (Aiken et al., 2011; Strickland et al., 2011). 
In relation to nutrient metabolism, modified endocrine function and hormone 
secretion may also play a role in decreased livestock productivity. The synthetic ergot 
alkaloid bromocriptine is known to activate D2 receptors and block D1 receptors, as well 
as cause partial agonism of 5-HT2B serotonin receptors and inhibition of 5-HT2A 
receptors; resulting in reduced blood glucose and serum triglycerides, and decreased body 
weight (Kalra et al., 2011; Lopez Vicchi et al., 2016). Bromocriptine also directly 
activates the α2 adrenergic receptors, inhibiting glucose-stimulated insulin secretion in 
pancreatic beta cells (Kalra et al., 2011; Lopez Vicchi et. al., 2016). The exact 
mechanism of action of ergot alkaloids at the pancreas is still not very clear. Intravenous 
administration of an ergotamine bolus to cattle has been shown to decrease plasma 
insulin concentrations and increase glucagon within 1 hour of dosing (Browning et al., 
2000).  
One attempt to improve the performance of stocker cattle grazing endophyte 
infected tall fescue is the use of steroidal implants, which have been shown to increase 
ADG in animals eating infected pasture (Brazle and Coffey, 1991; Beconi et al., 1995; 
Aiken et al., 2006; Carter et al., 2010). Androgenic and estrogenic steroids have been 
used for decades to enhance feed efficiency, rate of gain, and muscle gain in feedlot 
cattle. Combined treatment of cattle with estradiol and trenbolone acetate results in an 
increased number of muscle satellite cells, increased expression of IGF-1 mRNA in 
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muscle tissue, and increased levels of circulating IGF-1 (Dayton and White, 2014). It is 
currently believed that local production of IGF-1 in skeletal muscle plays a role in 
supporting normal muscle growth and that it is at least partially responsible for the 
increased number of satellite cells, increased hypertrophy and increased muscle growth 
observed in anabolic steroid-treated animals (Kamanga-Sollo et al., 2008b). However, 
Davenport et al. (1993) demonstrated that cattle grazing endophyte-infected pastures not 
only had lower rates of gain compared to controls, but also exhibited a slight decrease in 
IGF-1 responsiveness to estradiol-17β.   
IGF-1 and insulin are also important stimulators of the mTOR pathway, which in 
turn is responsible for protein synthesis and muscle gain in growing animals (Yoon, 
2017). Ergot alkaloids and structurally similar chemicals (indoles) have been shown to 
inhibit the growth hormone axis when given by intraperitoneal injection to rats (Flückiger 
et al., 1978) and the mTOR pathway in cancer cells (Ahmad et al., 2013), respectively. 
This led to the hypothesis that ergot alkaloids negatively affect the mTOR pathway and 
protein synthesis. The objective of the current study was to determine if fescue-derived 
alkaloids decrease muscle protein synthesis though inhibitory action on the mTOR 
pathway via a direct effect on signal proteins, and if these negative effects can be 
alleviated by implantation with anabolic agents. 
Materials and Methods 
 All procedures used in this study were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. Experiments were conducted at the 
University of Kentucky C. Oran Little Research Center in the Intensive Research 
Building in Versailles, Kentucky. 
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Animal Management 
 32 Holstein steers (BW = 332.6 ± 54.6 kg) were used in a 6-week randomized 
complete block design experiment. Steers were housed indoors at thermo-neutral 
conditions (22°C) in individual 3 m x 3 m pens with ad libitum access to water. A 14 
h:10 h, light:dark cycle was established with lights turning on at 0600 h and off at 2000 h 
each day. Animals were fed a corn silage-based diet (Table 3.1) that exceeded 
maintenance energy and protein requirements. Steers were also housed in individual 1.25 
m x 2 m metabolism stalls for one week for quantitative collection of urine to measure 
whole-body protein dynamics. 
Experimental Design and Procedures 
 Before the start of the experiment, steers were blocked by weight and randomly 
assigned within block to one of four treatments arranged in a 2 x 2 factorial structure. 
Treatment factors consisted of a synthetic ergot alkaloid or carrier and commercial 
implant or no implant. Bromocriptine mesylate (Cayman Chemical, Ann Arbor, MI) was 
used as the source of ergot alkaloid and was delivered via i.m. injection in an ethanol 
carrier (14.02 mg/mL in 95% ethanol; 0.1 mg/kg of BW; Baldwin et al., 2016; McLean et 
al., 2020). Bromocriptine was reconstituted as working stock in 95% ethanol and diluted 
with saline so no more than 40% ethanol was given in a single injection. Carrier 
injections consisted of 95% ethanol diluted with saline (40% and 60%, respectively). The 
commercial implant used was Revalor-S (Merck Animal Health, Kenilworth, NJ), which 
contains 120 mg of trenbolone acetate (TBA) and 24 mg of estradiol 17β. The four 
treatments were (1) a negative control, CON (n=8), no implant and injection with carrier 
only; (2) BROMO (n=8), no implant and injection with bromocriptine ; (3) IMP (n=8), 
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implant and injection with carrier only; (4) B+I (n=8), implant and injection with 
bromocriptine. Beginning with the heaviest animals, one block per week was brought into 
the barn, until capacity was reached on week 3 (blocks 1-3). After 37 days, the 
experimental period was complete and one block per week exited the barn, then was 
replaced with the next block until capacity was reached again (blocks 4-6). This patten 
was repeated when block 7 and 8 entered the barn. Animals were adapted to the 
individual pens for five days before the start of treatment. Treatment began on day 1. 
Animals assigned the estradiol implant were implanted at this time and animals assigned 
the ergot alkaloid received an injection of bromocriptine, with injections given every 
three days (day 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, and 34). Injection protocol was 
based on a previous study comparing the bromocriptine treatment response with the 
response observed in cows fed endophyte-infected fescue seed; where bromocriptine 
given at this dosage elicited the same gene expression response in 90% of identified 
differentially expressed genes in mammary tissue (n = 866) (Capuco et al., 2018).  
 Steers were weighed weekly to ensure injection volumes were calculated properly 
and feed intake was adjusted, except during the week that they were confined to tie-stalls. 
Blood samples were also obtained weekly from each steer via jugular venipuncture using 
an 18 ga needle for prolactin analysis. Samples were immediately placed on ice and 
centrifuged within 30 min at 2,800 × g for 20 min. Plasma was frozen in 3 aliquots to 
prevent multiple freeze-thaw cycles and stored at -20°C until analysis. 
 On day 27, prior to moving steers into the tie-stalls, each animal was fitted with a 
14 ga jugular catheter. Before placement, the area was prepared by scrubbing with 
betadine, then a jugular catheter (MILA International, Inc., Florence, KY LA1415, 14 ga, 
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15 cm) was inserted and sutured in place. Then a sterile extension set was added and 
filled with heparinized saline to ensure patency. Antibiotic ointment was applied to the 
external insertion site and covered with gauze. The gauze and extension line were held in 
place with vet wrap and covered with a Velcro hernia belt/wrap. Jugular catheters were 
flushed on day 28, then covered until day 35 when they were checked for issues and 
replaced if necessary prior to muscle biopsies. 
Measurement of Protein Turnover 
On days 27 through 32, steers were moved to metabolism stalls for urine 
collection. Total urine output was collected by continuous suction using a rubber funnel 
system attached to the ventral portion of the abdomen, allowing urine to flow into a 
plastic collection vessel. Urine acidity was reduced to pH < 3 by adding 1 L of a 23.5% 
solution of H3PO4 to the collection vessel after each sampling to prevent ammonia N loss 
and microbial growth. In order to determine background enrichment of 15N in urinary 
urea, steers were fitted with collection harnesses on day 27 and urine was collected for 
approximately 15 hours prior to isotope infusion; a representative aliquot was taken for 
later analysis. Whole-body protein turnover was determined using a single pulse dose of 
[15N] glycine (98 atom percent excess; Cambridge Isotope Laboratories, Inc., Andover, 
MA) into the jugular vein given at 0730 h on day 28. The [15N] glycine infusate was 
prepared by dissolving [15N] glycine (3.0 mg/kg bodyweight; Duggleby and Waterlow, 
2005) in physiological saline (50 mL) and sterilizing with Millipore filtration (0.45 uM 
m; Millipore, Bedford, MA) (Wessels et al., 1997). After isotope administration, urine 
was sampled every 12 hours, during which urine weight was recorded and representative 
aliquots (2% by weight) were taken at 12, 24, 36, 48, 60, 72, 84, and 96 hours after the 
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pulse dose. Urine samples were kept separate for each collection time and stored at 0° C 
until analysis. On day 32, after the last collection, steers were returned to individual pens. 
To prepare samples for measuring 15N enrichment of urinary urea, urine samples 
were first analyzed for urea concentration using a Technicon AutoAnalyzer II (SEAL 
Analytical Inc., Mequon, Wisconsin) (Marsh et al., 1965). This was used to determine the 
volume of urine needed for each sample to contain 100 µmoles of urea during ion 
exchange clean up. Polypropylene cation exchange columns (Bio-Rad, Richmond, CA), 
filled with AG 50W-X8 ion exchange resin (100-200 mesh, H+ form, Bio-Rad, 
Richmond, CA) were charged with NaOH and HCl, then used to isolate urea from 
ammonia. Urine samples were diluted with ddH2O to reach the desired urea 
concentration, then transferred to the charged columns. The first 5 mL of filtrate was 
discarded, then 20 mL of ddH2O was added to the column, and the eluent was collected 
into a scintillation vial. Vials were dried in a circulating air oven at 55°C for 3 days, then 
2 mL 0.1 M phosphate buffer was added to each vial to solubilize the sample. 100 µL of 
reconstituted sample was then transferred to an Erlenmeyer flask containing 3 mL of 
phosphate buffer. A 5 x 25 mm strip of folded Whatman 934-AH filter paper with 30 µL 
of 2.5 M KHSO4 was placed in a stopper cup and attached to each flask. Then 0.2 mL 
urease type III (100 unit/mL, Millipore Sigma, St. Louis, MO) was injected into the 
flasks in order to convert urea N to NH3. Flasks shook for 1 h at room temperature. 
Subsequently, 0.2 mL 3 N NaOH was injected into the flasks to volatilize NH3, and they 
shook again for 1 h at room temperature. After resting 24 hours, stopper units were 
placed in a desiccator with an open container of concentrated H2SO4 and allowed to dry 
for 24 hours. Then filter paper was enclosed in tin capsules and submitted for commercial 
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analysis of 15N enrichment (UC Davis Stable Isotope Facility, Department of Plant 
Sciences, Davis, California) by automated mass spectrometry. 
Calculation of Protein Turnover 
 The [15N] glycine single dose urea end product method was used to measure 
whole-body protein turnover (Assimon and Stein, 1992; Wessels et al., 1997).  
Total protein turnover was calculated (described previously by Waterlow et al., 1978) as: 
Q = d/G 
Where Q is protein turnover (g N/d), d is the rate of urea N excretion (g/d) in urine on 
day 28, 29, and 30, and G is the fractional recovery (%) in urinary urea of 15N from [15N] 
glycine. The 15N enrichment of each urine sample, following the pulse dose, was 
corrected by subtracting background 15N enrichment.  
Whole-body protein synthesis was calculated as: 
PS = Q − N excretion 
Where PS is protein synthesis (g N/d), Q is protein turnover (g N/d), and N excretion is 
the amount of N excreted in urine. 
Muscle Biopsies  
 Prior to muscle biopsies, on day 34, the area of the surgical site in the paralumbar 
fossa was prepared by clipping hair. On day 35, biopsy procedures were conducted in 
standing animals.  The surgical site was aseptically scrubbed and anesthetized using a 19-
gauge 1-1/2 inch needle to inject bupivacaine into the area using an "inverted L" block, 
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following the dorsal edge of the spinal processes from the 12th and 13th rib to a point 
slightly below the biopsy area. After blocking, the area was re-scrubbed to prepare for 
surgery. Muscle biopsies were taken immediately before and 60 minutes after activation 
of the mTOR pathway with a rapid IV infusion of 50% glucose (sterile) at a dose of 0.25 
g/kg body weight (Mann et al. 2016). This dose of glucose was shown to increase muscle 
mTOR signaling in muRF1, Akt, 4E-BP1, and ERK 1/2 proteins in dairy cows 
transitioning from dry to in milk (Mann et al. 2016). A vertical incision (approx. 3 cm 
long) was made through the skin of the paralumbar fossa, then adipose layer and fascial 
layer were removed to expose the musculus obliquus externus abdominis. Using forceps 
and a scalpel, approximately 300 mg of muscle was removed and processed for protein 
analysis. The skin incision was closed using Supramid (B. Braun Medical Inc., 
Bethlehem, PA) and a cruciate suture pattern. Post-biopsy care included treatment with 
meloxicam (1 mg/kg body weight; Covetrus, Dublin, OH) for 2 days and antibiotic 
ointment over skin incision sites. Muscle tissue samples were processed for extraction 
and quantification of mTOR pathway proteins. Immediately following removal from the 
animal, muscle tissue was minced and weighed; an aliquot (approximately 100 mg) was 
added to 700 µLhomogenizing buffer (20 mM HEPES, 2 mM EGTA, 50 mM NaF, 100 
mM KCL, 0.2 mM EDTA, 50 mM β-glycerophosphate) containing 14µL/mL of a 
protease/phosphatase inhibitor cocktail (Thermo Fisher Scientific Inc., Waltham, MA), 
then processed using a Tissue-Tearor homogenizer (BioSpec Products Inc., Bartlesville, 
OK). Homogenized sample was centrifuged at 10,000 x g for 10 minutes at 4° C. The 
resulting supernatant was removed and placed in three cryovials and stored at -80° C 
until further analysis. Any extra muscle tissue was flash frozen in liquid nitrogen and 
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stored at -80° C in a cryovial. Additionally, baseline blood samples (10 mL) were taken 
at 15 and 5 min before and 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, and 120 min after 
completion of the intravenous glucose bolus infusion and processed as previously 
described, for subsequent determination of glucose and insulin concentrations. Following 
collection of the final blood sample, the catheter was removed, and animals were 
observed in individual pens for 48 h before being housed in outside pens and returned to 
the herd. 
Western Immunoblot Analysis 
 Muscle samples were analyzed by western immunoblotting for the abundance and 
phosphorylation of proteins associated with the regulation of muscle protein synthesis 
(mTOR, p70 S6 Kinase, and 4E-BP1)  based on previously described methods (Wagner 
and Urschel, 2012; Mastro et al., 2014). First, total protein content of sample homogenate 
was determined using a Bradford assay (Bradford Reagent; VWR International, Radnor, 
PA), then samples were diluted to 4 μg/µL in Laemmli buffer (Bio-Rad Laboratories, 
Hercules, CA). SDS-PAGE was performed by loading 40 μg of total protein per sample, 
into gels containing different percentages of polyacrylamide (percentage noted below), 
made in laboratory (Laemmli, 1970). For each assay, all samples from one block were 
run at the same time in duplicate gels to eliminate interassay variation. Proteins were 
transferred to a 0.45 µm polyvinylidene deflouride membrane (Millipore Sigma, St. 
Louis, MO). Immediately after transfer, membranes were stained with Fast Green stain 
(0.2 g fast green, 50% methanol, 10% glacial acetic acid), which binds to all protein on 
the membrane, to check for success of protein transfer. A picture was taken of the stained 
membrane using an Azure c600 digital imager (Azure Biosystems, Dublin, CA), and this 
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image was later used to correct for loading errors. After imaging, Fast Green Stain was 
removed with destain (50% methanol, 10% glacial acetic acid) and buffer washes. Then 
membranes were blocked by incubation with 5% (w/v) fat-free milk dissolved in TBST 
for 1 hr at room temperature. After blocking solution was removed, membranes were 
probed with primary antibody for the phosphorylated form of each protein overnight at 4° 
C. All antibodies were validated in our lab for use with bovine muscle tissue (See 
Appendix A.1). 
Quantification of mTOR. Protein immunoblot analysis was performed using a rabbit 
monoclonal antibody, diluted in 5% (w/v) BSA dissolved in TBST that recognizes site-
specific phosphorylation of mTOR at Ser2448 or total mTOR (8% gel; 1:1000 dilution, 
catalog #5536 and #2983, respectively, Cell Signaling Technology, Danvers, MA). 
Antibodies were raised against human proteins. Band density of phosphorylated mTOR 
was normalized to band density of total mTOR. 
Quantification of S6K. Protein immunoblot analysis was performed using a rabbit 
monoclonal antibody, diluted in 5% fat-free milk dissolved in TBST, that recognizes site-
specific phosphorylation of S6K at Thr389 or total S6K (8% gel; 1:1000 dilution, catalog 
#9234 and #2708, respectively, Cell Signaling Technology, Danvers, MA). Antibodies 
were raised against human proteins. Band density of phosphorylated S6K was normalized 
to band density of total S6K. 
Quantification of 4E-BP1. Protein immunoblot analysis was performed using a rabbit 
monoclonal antibody, diluted in 5% fat-free milk dissolved in TBST, that recognizes site-
specific phosphorylation of 4E-BP1 at Thr37/46 or total 4E-BP1 (12% gel; 1:1000 
dilution, catalog #2855 and #9644, respectively, Cell Signaling Technology, Danvers, 
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MA). Antibodies were raised against mouse proteins. Band density of phosphorylated 
4E-BP1 was normalized to band density of total 4E-BP1. 
 After removing the primary antibody, membranes were washed and incubated 
with a goat anti-rabbit IgG secondary antibody conjugated with horseradish peroxidase 
(1:2000 dilution in 5% fat-free milk dissolved in TBST, catalog #7074, Cell Signaling 
Technology, Danvers, MA) for 1h at room temperature. Membranes were developed 
using a chemiluminescent kit (Amersham ECL Plus western blotting detection reagent, 
GE Healthcare Bio-Sciences, Pittsburgh, PA) and visualized using the Azure c600 
imaging system (Azure Biosystems, Dublin, CA). Following image capture, membranes 
were stripped for 10 min with stripping buffer (2% SDS, 62.5 mM Tris-Base, 0.1 M β-
mercaptoethanol), blocked with 5% fat-free milk blocking solution and re-probed with 
primary antibody for the total form of each protein.  
 Band densities of all blots and Fast Green stained membranes were quantified 
using densitometry software (AzureSpot Analysis Software, Azure Biosystems, Dublin, 
CA). To control for intra-assay variation, each sample band was normalized to the band 
density of a positive control (pooled bovine muscle homogenate samples), which was 
loaded onto each gel. To correct for possible gel loading errors, all band densities 
(phosphorylated and total protein abundance) were normalized to the value of total 
protein in each respective lane, determined by the densitometry software as “total lane 
volume” of the Fast Green stained membranes (See Appendix A.2). The band density of 
phosphorylated 4E-BP1, p70-S6K, and mTOR was then normalized to that of the total 
abundance of each respective protein. The calculated ratio of phosphorylated to total 
protein serves as a measure for activation status of these proteins, and relevant 
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differences in phosphorylated and total protein abundance will also be discussed. All 
obtained values are expressed as relative abundances in arbitrary units. 
Plasma Analysis 
Weekly blood samples were obtained from each steer via jugular venipuncture 
into vacutainer tubes with EDTA (Becton, Dickinson and Company, Franklin Lakes, NJ). 
The samples were processed immediately and centrifuged at 2000 x g for 10 min at 4 °C, 
after this plasma was removed and aliquoted before being stored at -20 °C. Subsequently, 
plasma prolactin concentrations were measured in duplicate as described previously 
(Forrest et al., 1980) using reagents for bovine prolactin provided by the National 
Hormone and Peptide Program (Dr. A.F. Parlow, Harbor-UCLA Medical Center, 
Torrance, Ca). Intra- and inter-assay coefficients of variation were 5.8% and 8.3%, 
respectively.  
Blood samples collected on the day of muscle biopsies were taken via jugular 
catheter 15 and 5 min before the animal received an intravenous glucose bolus and 0, 5, 
10, 15, 20, 25, 30, 45, 60, 90, and 120 min after the glucose bolus infusion. All samples 
were collected with sodium heparin and centrifuged as soon as possible. Plasma was 
removed and aliquoted before storage at -20 °C. Plasma glucose concentrations were 
determined using a biochemical analyzer (Konelab 20XTi, Thermo Electron Corp., 
Waltham, MA).  Intra- and inter-assay coefficients of variation were 1.1% and 3.6%, 
respectively. 
Plasma insulin levels were assayed using a commercially available 
radioimmunoassay kit (Porcine insulin RIA, Millipore Sigma) which had previously been 
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used for analysis of bovine insulin and validated in our lab. All samples for each assay 
were run in duplicate and within the same day. Insulin intra-assay coefficient of variation 
for low and high quality controls was 2.2% and 3.13%, and inter-assay coefficient of 
variation for low and high quality controls was 4.65% and 4.66%, respectively. 
Data Analysis 
 All data for dry matter intake, body weight, plasma prolactin, protein metabolism, 
plasma insulin and glucose, as well as baseline protein expression before glucose infusion 
and the change after infusion were analyzed as a randomized complete block design 
using mixed or glimmix procedures of SAS (version 9.4; SAS Institute, Cary, NC) with 
significance considered at P < 0.05 and statistical trends considered at 0.05 < P < 0.10. 
Terms in the model included bromocriptine, implant, and the implant x bromocriptine 
interaction, in a 2x2 factorial structure, with block specified as a random effect. When 
fixed effects were significant, least square means were compared using Fisher’s LSD 
procedures. Area under the response curve (AUC) was determined for prolactin, insulin 
and glucose using GraphPad Prism (v. 5.01, San Diego, CA). Area under the curve, time 
to peak and peak plasma concentrations were analyzed for insulin, glucose, and prolactin. 
The response of protein expression to glucose infusion determined by western 
immunoblot was analyzed as the difference between baseline (pre-infusion) values and 
post-infusion (60 min) values of each dependent variable. Additionally, post-infusion 
values were also analyzed using each animal’s baseline values as covariates to determine 
if pre-infusion values affected post-infusion values and if this could be influenced by 
treatment. For covariate analysis, we first evaluated independent slope models by testing 
baseline values (pre) and interactions between baseline values and treatment as fixed 
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effects (pre, pre x bromo, pre x implant, and pre x bromo x implant) to determine which 
covariates were significant (P < 0.05). When interactions were not significant, interaction 
terms were dropped to evaluate common-slope covariate models. Insignificant covariates 
were dropped from the model. Graphs were created with GraphPad Prism (v. 5.01, San 
Diego, CA). 
 Model assumptions were assessed by evaluation of homogeneity of variances and 
normality of studentized residuals. For each data set, the homogeneous and 
heterogeneous models were compared for best fit using the BIC criterion. The model with 
the lowest BIC was preferred. Then, normality of the data was assessed by visual 
inspection of the distribution of studentized residuals, Q/Q plots, and a Shapiro-Wilk test 
(P < 0.05). Observations that disrupted normal distribution, with studentized residuals ≥ 
3, were considered outliers and were removed from the datasets to obtain normal 
distribution. Four animal observations (two from CON, one from IMP, and one from 
B+I) were removed from the prolactin dataset based on distribution of residuals, all were 
over 3, and visual assessment of the data. One animal observation (BROMO) was 
removed from the weight gain dataset for d 8-15 based on a residual over 3 and weight 
gain that was unusually high from visual observation of the dataset. Seven animal 
observations (one from CON, two from BROMO, two from IMP, and two from B+I) 
were removed from the protein metabolism dataset based on urine collection errors and 
visual observation of the data. One more animal observation (B+I) was removed from the 
dataset based on residuals that were over 3 and irregularly high urea excretion and 
fractional recovery, which effected calculation of protein turnover and synthesis. Lastly, 
four animal observations were removed from the western immunoblot datasets based on 
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distribution of residuals. The following observations, with residuals over 3, were 
removed: one from activation status, pre-infusion mTOR (CON), one from 
phosphorylated, post-infusion mTOR (IMP), one from activation status, pre-infusion S6K 
(IMP), and one from total, post-infusion S6K (BROMO). 
Results 
 Throughout the 35-day experiment, DMI was restricted to 1.5 times maintenance 
energy requirement. This was done to minimize potential differences in DMI across 
treatments and thus prevent the influence of DMI on the measured variables, while 
ensuring sufficient energy and nutrient intake to support muscle accretion. Accordingly, 
DMI was the same for all treatments (P ≥ 0.22). The average BW at enrollment was 
332.56 ± 54.55 kg and did not differ between treatment groups (P ≥ 0.29). Weekly BW 
measurements were taken from day 1 at the start of treatment administration to day 22 
(Table 3.1). There was a trend (P = 0.07) for implanted steers to have higher gains during 
the first week, but bromocriptine showed no influence (P =0.79) on gain. Treatment 
differences were not significant until week two, during which weight gain was greater (P 
= 0.01) in implanted animals and less (P = 0.04) in bromocriptine treated animals. During 
the third week, implanted steers had higher (P = 0.02) gains, while those receiving 
bromocriptine showed no differences in gain (P = 0.12). Overall, total gain and ADG 
were higher in implanted steers (P < .0001), regardless of bromocriptine administration; 
and bromocriptine alone caused steers to gain less than control animals (P = 0.01). There 
were no treatment interactions (P ≥ 0.15) associated with weight gain during this 
experiment. 
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Plasma Prolactin 
 Weekly plasma prolactin concentrations are shown in Figure 3.1 and area under 
the curve measuring prolactin concentration over time are shown in Table 3.1. Before 
treatment began, there were no differences in circulating prolactin between groups (P ≥ 
0.24) and there were no interactions. Steers that received bromocriptine injections 
experienced a sharp drop in prolactin after the first week of treatment (Day 8, P = 0.04) 
and maintained those depleted levels during week two (Day 15, P = 0.001) and three 
(Day 22, P = 0.002) (Figure 3.1). Consequently, prolactin AUC in steers treated with 
bromocriptine (1,803 ± 347) was significantly lower (P = 0.002) than the AUC of steers 
that were not treated with the alkaloid (3,278 ± 367). Prolactin concentrations were not 
different in steers treated with implant during the first 2 weeks of treatment (Day 8 & 15, 
P ≥ 0.45) and there were no interactions (Day 8 & 15, P ≥ 0.34). However, during the 
third week of treatment, implanted steers had significantly lower concentrations of 
prolactin (Day 22, P = 0.02) and there was a treatment interaction (Day 22, P = 0.01). 
During the fourth week of treatment circulating prolactin was not different between 
treatment groups (Day 29, P ≥ 0.53) and there was no treatment interaction (Day 29, P = 
0.49). Despite this, implant treatment had no effect (P = 0.61) on prolactin AUC and 
there were no treatment interactions (P = 0.45) associated with prolactin. 
Protein Turnover 
 Whole-body protein metabolism determined by [15N] glycine infusion and urine 
collection are shown in Table 3.2. Urinary excretion of urea (g/d) was lower (P = 0.006) 
in steers treated with estradiol implants. In contrast, bromocriptine had no effect (P = 
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0.13) on urea excretion and there was no treatment interaction (P = 0.87). The fractional 
recovery of labelled glycine from urine 48 hours after infusion, was lower (P = 0.03) in 
implanted steers, but no differences (P = 0.30) were seen in bromocriptine steers. There 
was no treatment interaction (P = 0.87). Protein turnover tended to be lower in steers 
given estradiol implants (131.7 ± 7.8 g N/d) than in those that did not receive an implant 
(141.9 ± 7.5 g N/d) (P = 0.10), but there was no effect (P = 0.43) of bromocriptine on 
turnover. However, this was not true regarding protein synthesis, since neither estradiol 
implants nor bromocriptine treatment were able to alter the amount of protein synthesized 
(P ≥ 0.47). Treatment interactions were not present for protein turnover or protein 
synthesis (P ≥ 0.52). 
Plasma Glucose  
 Plasma glucose concentrations in response to an intravenous glucose bolus are 
shown in Figure 3.2. The maximum concentration or peak height (Table 3.3) of blood 
glucose occurred at 5 min post infusion and was not different between treatment groups 
(P ≥ 0.70) and there was no treatment interaction (P = 0.32). There was a trend (P = 0.09) 
for AUC to be higher in steers treated with bromocriptine (17,155 ± 687 mg/dL) in 
comparison to steers not treated with bromocriptine (16,206 ± 687 mg/dL). Total AUC 
was not affected by estradiol implants (P = 0.73) and there was no treatment interaction 
(P = 0.45). 
Plasma Insulin 
 Plasma insulin concentrations in response to an intravenous glucose bolus are 
shown in Figure 3.3. The time to peak insulin concentration (Table 3.4) was between 15- 
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and 20-minutes post glucose infusion, and there was a trend (P = 0.09) for bromocriptine 
treated steers (18 ± 2 min)  to take longer to reach peak insulin levels compared to steers 
that did not receive bromocriptine (15 ± 1 min). Time to peak was not affected by 
implant (P = 0.29) and there was no treatment interaction (P = 0.29). The maximum 
concentration (peak height) of insulin showed no differences (P ≥ 0.79) between 
treatment groups and exhibited a tendency (P = 0.07) for a treatment interaction. In the 
absence of bromocriptine, maximal concentration was lower for implanted steers, 
whereas in the presence of bromocriptine maximal concentration was higher for 
implanted steers. The insulin AUC of steers treated with bromocriptine (10,496 ± 818) 
was higher (P = 0.04) than that of untreated steers (8,052 ± 818). However, there was a 
tendency (P = 0.07) for a treatment interaction like that observed for peak height. In 
response to implant, insulin AUC was slightly decreased or unchanged in the absence of 
bromocriptine but was increased in the presence of bromocriptine. 
Western Immunoblots 
 There was an overall effect of bromocriptine on total abundance of mTOR protein 
in the pre-infusion state (Table 3.5); steers that received bromocriptine had greater (P = 
0.05) pre-glucose infusion levels of total mTOR than those that did not. Baseline levels 
were not affected by implant status (P = 0.55) and there was no treatment interaction (P = 
0.14). Conversely, pre infusion levels of phosphorylated mTOR and the activation status 
(phosphorylated protein:total protein) were not affected (P ≥ 0.19) by treatments  and 
there were no treatment interactions (P ≥ 0.12). Post-infusion values of total abundance 
of mTOR protein were not affected (P ≥ 0.20) by bromocriptine or implant treatment and 
there was no treatment interaction (P =0.76). There was a significant effect of 
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bromocriptine treatment on the post-glucose infusion phosphorylation of mTOR (P = 
0.04) with steers receiving bromocriptine having a greater degree of phosphorylation, but 
following glucose administration, there was no significant effect of bromocriptine 
treatment on the activation status (ratio of phosphorylated to total) of mTOR (P = 0.38). 
The implant treatment did not affect (P ≥ 0.14) phosphorylated mTOR abundance, or 
activation status. There were no treatment interactions (P ≥ 0.42) for phosphorylated 
mTOR or activation status. Additionally, it was determined that pre glucose infusion 
levels of phosphorylated mTOR affected the amount of phosphorylated mTOR found 
post infusion, but only in animals treated with bromocriptine (P = 0.0012; pre infusion-
by-bromocriptine interaction). For steers receiving bromocriptine, there was a positive 
relationship between pre- and post- infusion abundance; post-infusion abundance of 
phosphorylated mTOR increased with pre-infusion abundance (Figure 3.4). However, in 
the absence of bromocriptine, there was no relationship between pre- and post- infusion 
phosphorylated protein abundance. The pre covariate also affected (P = 0.01) post 
infusion values of total mTOR for all treatments; in this instance, as pre-infusion values 
increased, so did post-infusion values of total mTOR. There were no significant (P ≥ 
0.96) covariates for activation status. 
 Total and phosphorylated protein abundance and activation status for S6K1 prior 
to glucose infusion was unaffected (P ≥ 0.12) by implant or bromocriptine treatment and 
there were no treatment interactions (P ≥ 0.12; Table 3.6). Similarly, post-infusion 
protein abundance of phosphorylated S6K1 and its activation status was unaffected (P ≥ 
0.17) by treatment. Post-infusion abundance of total S6K1 was unaffected (P= 0.40) by 
implant, however, abundance was lower (P= 0.05) for the bromocriptine treated steers 
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compared with those not treated with bromocriptine. There were no (P ≥ 0.28) post-
infusion treatment interactions observed for S6K1. It was also determined that the pre 
covariate affected (P < .0001) total S6K1, so that animals treated with implants and 
bromocriptine had the highest pre-glucose infusion levels of total S6K1, but had the 
lowest abundance of post-infusion total S6K1. Animals not treated with implants and 
bromocriptine had low levels of total S6K1 pre-infusion and the highest levels of 
abundance post-glucose infusion. There were no significant covariates for activation 
status or phosphorylated S6K1 (P ≥ 0.17). 
 Pre infusion levels of total and phosphorylated 4E-BP1 protein, as well as 
activation status, (Table 3.7) were not affected (P ≥ 0.30) by bromocriptine or implant 
treatment. However, there was a tendency for implant to increase the abundance of total 
4E-BP1 in the absence, but not in the presence of bromocriptine treatment 
(bromocriptine-by-implant interaction, P = 0.06); there were no other pre-infusion 
interactions (P ≥ 0.15). Post-infusion abundance of total 4E-BP1 was lower in both the 
bromocriptine (P = 0.005) and implant (P = 0.04) treated animals compared to those that 
did not receive bromocriptine or implant, respectively. The lower total 4E-BP1 
abundance for both implant and bromocriptine treatment, however, is largely explained 
by lower abundance for the implant treatment in the absence, but not in the presence of 
bromocriptine (bromocriptine-by-implant interaction, P = 0.10). The abundance of 
phosphorylated 4E-BP1 (P = 0.02) and activation status of 4E-BP1 (P = 0.01) were 
decreased with implant treatment, while bromocriptine had no effect on abundance (P = 
0.60) or activation status (P = 0.11). There were also no treatment interactions (P ≥ 0.34) 
for post-infusion phosphorylated 4E-BP1 and activation status. Additionally, it was 
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determined that pre glucose infusion levels of total 4E-BP1 affected (P < .0001) the 
amount of total 4E-BP1 found post infusion. Animals treated with implants and 
bromocriptine had the highest pre-infusion levels of total 4E-BP1 and the lowest 
abundance of post-infusion total 4E-BP1 protein; animals not treated with implants or 
bromocriptine had the lowest levels of total 4E-BP1 pre-infusion but did not demonstrate 
a change in protein abundance. In animals treated with bromocriptine (P = 0.003; pre 
infusion-by-bromocriptine interaction), the decline in post-infusion abundance of total 
4E-BP1 was not as severe as that seen in implanted animals following glucose infusion 
(Figure 3.5). The pre covariate also affected (P = 0.01) post infusion values of 
phosphorylated 4E-BP1 for all treatments, in this instance, as pre-infusion values 
increased, post-infusion values of phosphorylated 4E-BP1 decreased. There were no 
significant (P ≥ 0.30) covariates for activation status. 
Discussion 
 The purpose of this study was to determine if fescue-derived alkaloids affect 
whole-body protein metabolism and decrease muscle protein synthesis by directly 
inhibiting the mTOR pathway via signaling proteins, and if so, if such negative effects 
can be alleviated by implantation with anabolic agents. Previous research has shown that 
cattle given an anabolic steroid implant while grazing endophyte infected fescue will 
have improved performance compared to cattle consuming infected pasture without an 
implant (Aiken et al., 2006; Beconi et al., 1995; Brazle and Coffey, 1991) — how this is 
achieved has not been determined. Steroidal implants are known to increase production 
of IGF-1 in skeletal muscle, which is at least partially responsible for the increased 
muscle growth and weight gain observed in implanted animals (Kamanga-Sollo et al., 
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2008); this is possibly the source of improved performance in cattle affected by ergot 
alkaloids. IGF-1 and insulin are important stimulators of the mTOR pathway, which in 
turn is responsible for protein synthesis and muscle gain in growing animals (Yoon, 
2017). Ergot alkaloids and structurally similar chemicals (indoles) have been shown to 
inhibit the growth hormone axis (Flückiger et al., 1978) and the mTOR pathway (Ahmad 
et al., 2013), respectively, in other species. This experiment is the first to demonstrate the 
effects of ergot alkaloids and estradiol implants on the mTOR pathway in the skeletal 
muscle of cattle. 
Plasma Prolactin 
 Decreased circulating prolactin is one of the few measurable parameters available 
to diagnose fescue toxicosis (Schillo et al., 1988). Lactotrophs in the pituitary gland are 
responsible for the synthesis and secretion of prolactin; release of prolactin from these 
cells is controlled by D2-dopamine receptors and is inhibited by high levels of dopamine 
(Freeman et al., 2000). Ergot alkaloids are structurally similar to dopamine, allowing 
alkaloids to bind and activate these receptors and reduce circulating prolactin (Berde and 
Stürmer, 1978). Bromocriptine is a synthetic ergopeptine that also activates dopamine 
receptors in the pituitary, and therefore imitates the actions of naturally occurring ergot 
alkaloids on prolactin secretion (Fitzgerald and Cunningham, 1982; Freeman et al., 
2000). A fescue toxicosis-like syndrome can be induced using bromocriptine injections 
and has previously been shown to decrease prolactin in steers and cows (McLean et al., 
2020; Baldwin et al., 2016). It has also been demonstrated that 90% of differentially 
expressed genes (DEG) (n=866) in mammary tissue respond similarly in both 
bromocriptine treated cows and those fed fescue-derived alkaloids (Capuco et al., 2018); 
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indicating that bromocriptine provides a satisfactory model for studying physiological 
changes in cattle affected by fescue derived alkaloids. In the current study, while 
prolactin appeared to decrease over time with all treatments (the exception being the 
increase from d1 to d8 for CON), prolactin in steers treated with bromocriptine decreased 
very sharply on d8 and stayed at nadir levels throughout the study — resulting in an 
overall decrease in area under the curve (AUC) for bromocriptine treated steers. Estradiol 
has previously been shown to stimulate prolactin release in male rats (Seo et al., 1979) as 
well as increase prolactin levels in the serum and milk of dairy cattle (Tong et al., 2018). 
It is unclear why prolactin decreased throughout the course of the study in the steers not 
treated with bromocriptine. Light is an important regulator of prolactin secretion, with 
shorter photoperiods resulting in decreased prolactin (Freeman et al., 2000). In 
preparation for the experiment, animals were housed outside from April to July, when 
there are 12-14 hours of light per day, then during the experimental period they entered a 
facility with an established 14 h:10 h, light:dark cycle. Since there was no change, or 
even an increase in photoperiod length when animals moved inside, this effect of light on 
prolactin secretion cannot account for the decrease in circulating prolactin seen in 
animals not treated with bromocriptine. While there is no explanation for this decrease 
over the course of the experiment, the decrease seen with bromocriptine treatment was 
more severe, indicating that a fescue toxicosis-like syndrome was induced in the current 
experiment. 
Dry Matter Intake and Weight Gain 
 The diet used in this study was designed to meet the recommended nutrient intake 
of growing steers. To prevent the results being confounded by dry matter intake, we 
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limited intake to 1.5x maintenance to ensure the daily feed allotment was consumed by 
all animals, regardless of any possible effects from treatments. This was especially 
important because ergot alkaloid consumption has been shown to decrease feed intake 
(Schmidt et al., 1982; Baldwin et al., 2016).  The agonistic action of alkaloids on 
serotonin receptors is thought to affect satiety and gastrointestinal motility (Simansky, 
1995; Talley, 1992). Although bromocriptine treated animals always consumed their 
daily meal, their ADG was lower than animals not treated with bromocriptine 
(bromocriptine steers gained 0.15 kg BW less per day than steers not treated). This 
demonstrates the decreased growth performance that is a common symptom of fescue 
toxicosis (Walker, 2009) and highlights that this impairment exists even in the absence of 
differences in DMI. Implants containing estradiol are commonly used to enhance steer 
performance and have been shown to improve the gains of cattle grazing endophyte 
infected pastures (Aiken et al., 2006; Beconi et al., 1995; Brazle and Coffey, 1991), but 
this is the first instance where the dry matter intake of animals was controlled. 
Implantation increased ADG in both the presence (B+I steers gained 0.19 kg BW more 
per day than CON) and absence (IMP steers gained 0.41 kg BW more per day than CON) 
of bromocriptine, demonstrating that estradiol implants can improve weight gain, even 
when intake is controlled. This shows that there were pronounced benefits of steroidal 
implantation on ADG, further demonstrating the value of implants use for growing cattle 
exposed to endophyte infected tall fescue. 
Glucose Homeostasis  
 Thus far, research has primarily focused on the detrimental effects of ergot 
alkaloids on animal production and the beneficial growth promoting effects of hormonal 
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implants, but very little is known about the impact these chemical alterations have on 
glucose homeostasis in cattle. Bromocriptine has central and peripheral actions on the 
autonomic nervous system and the endocrine system in rats and humans (Kalra et al., 
2011). Its effects on pancreatic β-cells, and therefore glucose homeostasis, have made it 
an important treatment option for type 2 diabetes in humans, as it improves glucose 
tolerance and insulin sensitivity (Kalra et al., 2011).  
 In the current study, an intravenous glucose tolerance test (IVGTT) was used to 
activate the mTOR pathway and assess the first phase of insulin release. The resulting 
insulin curve shows that bromocriptine tended to delay the rise in plasma insulin levels; 
Steers not treated with bromocriptine peaked at 15 min post glucose infusion, while B+I 
steers peaked at 16.25 min and BROMO peaked at 20 min post infusion. This delay with   
bromocriptine treatment cannot be attributed to a delay in glucose time to peak because 
time to peak for glucose was similar across all treatments.     
 Implanted steers tended to have increased insulin peak height in the presence of 
bromocriptine, but in the absence of bromocriptine there were no differences. This 
increase in maximal concentration, paired with decreased insulin clearance, resulted in a 
tendency for B+I steers to have an insulin AUC that was higher than either treatment 
alone (33.08% and 37.46% higher AUC than BROMO and IMP, respectively). Due to the 
lack of research concerning the effects of implantation combined with ergot alkaloids on 
glucose homeostasis, an explanation must be derived from our current understanding of 
the independent effects of steroidal implants and ergot alkaloids on animals. 
 The affinity of ergot alkaloids for the receptors of biogenic amines such as 
dopamine and norepinephrine in the pancreas may help explain the endocrine responses 
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seen in bromocriptine treated animals. Although research in this area is limited in cattle, 
ergot alkaloids have been shown to decrease insulin and increase glucagon in heifers 
within 1 h of a single dose of ergotamine tartrate injection (Browning et al., 2000). 
Dopamine type-2 receptors are expressed in the pancreatic β-cells of humans, rats, and 
mice; allowing dopamine to mediate inhibition of insulin secretion (García-Tornadú et 
al., 2010; Rubí et al., 2005). Insulin secretion typically starts with glucose-induced 
electrical activity of β-cells which leads to the opening of voltage-gated calcium 
channels, Ca2+ influx, and Ca2+-dependent exocytosis of insulin (Lang, 1999). Dopamine 
decreases cell membrane depolarization and cytosolic Ca2+ entry, resulting in blunted 
insulin secretion in response to glucose stimulation (Rubí et al., 2005). Ergot alkaloids 
and bromocriptine are agonistic to D2 receptors (Schillo et al., 1988) allowing them to 
activate those receptors found in the pancreas and illicit the same response. Pancreatic β-
cells also express α2-adrenergic receptors, which mediate the effects of norepinephrine 
released from the hypothalamus, postganglionic sympathetic nerve endings and the 
adrenal medulla (Fagerholm et al., 2011; Lopez Vicchi et. al., 2016). Activation of these 
receptors by norepinephrine or α2-adrenoreceptor agonists such as bromocriptine leads to 
dysregulated glucose homeostasis and elevated blood glucose through potent inhibition of 
insulin secretion, increased glucagon secretion from the pancreas, and increased 
gluconeogenesis and glycogenesis in the liver (Fagerholm et al., 2011). Research in this 
area is limited in cattle and the complex interaction of alkaloids with various bioamine 
receptors make it difficult to identify a precise mode of action in this study.  
 Steroid hormone implants were expected to increase levels of IGF-1 in the current 
study, which in turn would affect insulin secretion by the pancreas. Estradiol-17β and 
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TBA implants have been shown to increase serum GH and IGF-1 in steers to levels 
comparable to intact bulls (Hunt et al., 1991; Lee et al., 1990) and steers given a Revalor-
S implant had increased IGF-1 mRNA levels in longissimus muscle compared to 
nonimplanted steers (Pampusch et al., 2003). IGF-1 receptors have been found on rat 
pancreatic β-cells, which allow the hormone to mediate a suppressive action on insulin 
release (Van Schravendijk et al., 1990). Elevated circulating IGF-1 binds to these 
receptors on the surface of β-cells, activating a series of kinases that eventually activate 
the phosphodiesterase, PDE3B. This causes a reduction of cAMP levels in the β-cells and 
attenuation of insulin release from pancreatic islets (Zhao et al., 1997). In humans, high 
levels of IGF-1 can directly stimulate glucose transport into muscle through either IGF-1 
or insulin/IGF-1 hybrid receptors (Clemmons, 2012) which may explain why glucose 
clearance from the blood was not affected in implanted steers.    
 There is limited research in cattle concerning the effects of ergot alkaloids on 
estradiol implants and circulating levels of IGF-1. Estradiol implants result in increased 
circulating IGF-1 in steers grazing pastures with low endophyte infection rates but not in 
steers grazing Kentucky 31 pasture with high endophyte infection rates (Davenport et al., 
1993). A single bolus injection of ergotamine tartrate in cattle has been shown to 
decrease plasma IGF-1 (Browning, 2003) and activation of D2 receptors by 
bromocriptine decreases growth hormone release in acromegalic patients, which inhibits 
GH-mediated antagonism of insulin (Lopez Vicchi et. al., 2016). Paradoxically, 
ergotamine tartrate and ergonovine maleate have been shown to elevate plasma growth 
hormone concentrations in normal steers (Browning et al., 1997). Perhaps bromocriptine 
treatment removes the suppressive action of growth hormone and IGF-1 on insulin 
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release, and therefore B+I animals show increased insulin secretion after the IVGTT. 
This does not account for all the effects on glucose homeostasis seen with combined 
bromocriptine and implant treatment. This result is likely due to a complex interplay of 
estradiol, growth hormone and IGF-1, in addition to bromocriptine and its activation of 
dopaminergic and adrenergic receptors in the pancreas. At this time, the exact mechanism 
of action for this novel response is unclear and requires further research to clarify what 
occurred in the current study. 
 Interestingly, the insulin response curve also shows that bromocriptine produced 
larger areas under the curve (AUC). Following peak insulin concentration, bromocriptine 
treated steers displayed higher insulin levels post peak, which continued until the end of 
sampling, they also took 30 mins longer than steers not treated with bromocriptine to 
drop to pre-infusion levels, indicating decreased insulin clearance. The reduced clearance 
rate of insulin occurs at the same time as the reduced clearance rate of glucose, indicating 
that bromocriptine decreased insulin sensitivity and explaining the tendency for glucose 
AUC to be higher in bromocriptine treated steers than in those not treated with 
bromocriptine. In lean mice, a single intraperitoneal injection of bromocriptine one hour 
before an intraperitoneal glucose tolerance test (ipGTT) has been shown to elevate blood 
glucose levels compared to mice that received a placebo, demonstrating acutely impaired 
glucose tolerance (de Leeuw van Weenen et al., 2010). The results of the current study 
and de Leeuw van Weenen et al., (2010) appear to contradict the improvements in 
glucose tolerance and insulin sensitivity seen in obese insulin resistant animals and 
humans treated with bromocriptine (Kalra et al., 2011). This disparity might stem from 
the use of healthy/lean animals instead of obese insulin-resistant animals. A similar 
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situation occurs with the pancreatic KATP activator diazoxide, another medication used 
to decrease insulin secretion, that also has opposite effects on glucose tolerance in lean 
and obese Zucker rats (Alemzadeh et al., 1993). While de Leeuw van Weenen et al., 
(2010) also found that bromocriptine delayed and reduced the rise in plasma insulin 
levels following the glucose challenge, their resulting AUC for total insulin release in 
bromocriptine treated mice was lower than placebos, unlike in the current study. These 
conflicting results may be due to species differences, or perhaps from the difference 
between single/acute treatment in the mice vs multiple/chronic treatment in the steers 
from the current study. 
Protein Turnover 
 DMI was restricted with the intention of minimizing effects of treatment on 
intake, allowing observation of direct changes in protein metabolism in tissues. 
Curiously, while total weight gain was decreased by bromocriptine in both the presence 
and absence of implantation, urea excretion was not affected by bromocriptine treatment.  
To our knowledge the effect of alkaloids on nitrogen metabolism has been studied only 
twice before in cattle. Unfortunately, in neither of those studies was DMI controlled to 
the extent of the current study, making direct comparisons difficult. Those studies 
demonstrated that steers fed E+ or E- tall fescue hay showed no differences in urinary 
urea N excretion (Huntington et al., 2009) or total urinary N (Matthews et al., 2005). 
Matthews et al., (2005) also determined that N retention was lower in steers fed E+ hay 
with 13.8 g N/d vs 22.4 g N/d in E- steers. It is uncertain whether the lower N retention 
observed was due to ergot alkaloid induced changes in nitrogen metabolism or loss of 
appetite due to fescue toxicosis, which would result in lower DMI and N intake in steers 
 
83 
 
consuming E+ fescue hay. Considering fecal and urinary N were not different, reduced N 
retention was most likely a function of reduced intake (Matthews et al., 2005). In the 
current study, there were also no differences in whole-body protein synthesis or protein 
turnover between bromocriptine treated steers and those not treated with bromocriptine. 
To the best of our knowledge, these aspects of protein metabolism in alkaloid treated 
animals have not been documented in any species. These preliminary findings suggest 
that the effects of ergot alkaloids do not stem from disruption of protein synthesis or N 
retention.   
 Urinary nitrogen is consolidated from three main sources: (1) urea and ammonia 
from catabolism of tissue, (2) urea and ammonia from fermentation in the rumen and 
cecum, and (3) non-urea and non-ammonia components of microbial and host animal 
origin (Lobley et al., 1985). Most excess nitrogen is excreted as urea, which comes from 
excess protein and amino groups that are not used by the body for protein synthesis, 
transamination, and recycling to the gastrointestinal tract (Reeder et al., 2011). Despite 
similar DMI among treatments in the current study, implanted steers showed increased 
growth rate, and lower urea excretion than non-implanted steers (implanted steers 
excreted 12 g/d less than non-implanted). Thus, it appears that N retention was higher in 
steers treated with estradiol/TBA implants. These possible improvements in N retention 
indicate a decrease in amino acid catabolism and should be accompanied by an alteration 
in the rate of protein synthesis and/or protein degradation. Similarly, steers with restricted 
DMI and implants (140 mg TBA/20 mg estradiol), excreted 85 g/d urinary nitrogen and 
had increased nitrogen retention, whereas controls excreted 100 g/d of urinary nitrogen 
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(Lobley et al., 1985). To our knowledge this is the only other study to observe the effects 
of a combined estradiol + TBA implant on nitrogen metabolism when DMI is controlled.  
 Additionally, there were no differences in whole-body protein synthesis between 
treatments, but protein turnover tended to be over 10 g N/d lower in implanted steers. 
Protein turnover is the net result of the continuous synthesis and breakdown of body 
proteins that is necessary to maintain protein function (Chou et al., 2012). This trend for 
lower turnover in steers that received steroidal implants stems from the unchanged rates 
of protein synthesis paired with decreased protein degradation. This was also 
demonstrated by Lobley et al. (1985), in that implant-treated steers showed a slight 
decline in synthesis 5 weeks post-implant, while amino acid oxidation was significantly 
lower 2- and 5-weeks post-implant compared to non-implanted animals. Increased 
protein deposition through a decrease in protein degradation, results in less energy 
expenditure for the animal, compared to increased protein deposition through an increase 
in protein synthesis. This is because of the relatively high energetic cost of protein 
synthesis, which requires at least 4.5 kJ/g (Lobley et al., 1985). Manipulation of whole-
body protein metabolism through the combined action of the exogenous steroids 
promotes protein accretion, allowing for the considerable weight gains accomplished by 
implanted animals. 
 This is possible through the strategic combination of estradiol 17β and trenbolone 
acetate (TBA). TBA has been shown to decrease protein synthesis and protein 
degradation in the muscle of female rats, but its effects on degradation seem more 
pronounced (Buttery, 1983). TBA is known to bind to a variety of receptors, including 
estrogen, progestin, androgen, and glucocorticoid (Raynaud et al., 1981). Androgenic 
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activity from TBA results in stimulation of growth hormone and IGF-1 secretion as well 
as lowering receptor sensitivity to endogenous glucocorticoids. When binding to 
glucocorticoid receptors, TBA almost completely suppresses tyrosine amino transferase 
(a key enzyme in amino acid degradation) in rat hepatocytes (Danhaive and Rousseau, 
1986; 1988). The strong growth-promoting potency of TBA derives from both its 
anabolic activity as an androgen and anticatabolic activity as an anti-glucocorticoid.  
 In cattle, estrogens are known to act in all strategically important tissues to reduce 
nitrogen excretion, and improve mineral retention, protein anabolism and protein 
deposition in skeletal muscle (Meyer, 2001). Direct action of estradiol on skeletal muscle 
through estrogen receptors (ER) as well as indirect action through stimulation of growth 
hormone secretion, GH-receptors in the liver, and IGF-1 secretion into the blood are all 
considered important influences of estradiol (Meyer, 2001; Dayton and White, 2014). 
The exact mechanism of action involved for implant-stimulated muscle growth in beef 
cattle is still uncertain, but studies indicate their effects on muscle satellite cells may play 
an important role (Johnson et al., 1998a; Kamanga-Sollo et al., 2008b; Pampusch et al., 
2008). It is currently believed that local production of IGF-1 in skeletal muscle plays a 
part in supporting normal muscle growth and an estradiol-induced increase in muscle 
IGF-1 mRNA expression contributes to the increased number of satellite cells, and 
increased rate and efficiency of muscle growth observed in anabolic steroid-treated 
animals (Kamanga-Sollo et al., 2008b; Dayton and White, 2014).  
 In the current study estradiol and TBA were used in conjunction to maximize 
metabolic changes and growth response. Implanted steers appeared to have higher N 
retention, indicating a decrease in amino acid catabolism and possibly an alteration in the 
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rate of protein degradation, as well as increased protein accretion and increased growth 
rates compared to non-implanted animals, even in the presence of bromocriptine. The 
detrimental effects of bromocriptine on weight gain may be due to the actions of ergot 
alkaloids on IGF-1 secretion. As mentioned previously, cattle given an estradiol implant 
and grazed on endophyte-infected pastures have been shown to not only have lower rates 
of gain compared to controls, but also a slight decrease in IGF-1 responsiveness to 
implantation (Davenport et al. 1993). Cattle injected with ergotamine tartrate have been 
shown to experience drops in plasma IGF-1 concentrations (Browning, 2003). 
Additionally, bromocriptine has also been shown to decrease growth hormone release in 
patients with acromegaly, which in turn leads to decreased circulating IGF-1 from the 
liver. Although bromocriptine may affect circulating IGF-1, there has been no research 
showing its effects on local production of IGF-1 in non-hepatic tissues. It is unknown if 
ergot alkaloids affect production of IGF-1 in skeletal muscle or muscle growth induced 
by IGF-1, estradiol, and TBA in cattle. Considering bromocriptine did not have any effect 
on nitrogen excretion, protein turnover, and protein synthesis, the stunted weight gain in 
bromocriptine treated cattle may not be from an effect on protein accretion but rather 
glucose metabolism in skeletal muscle and protein degradation signals through the 
mTOR pathway. 
Western Immunoblots 
 The mTOR signaling pathway plays a central role in regulating cell growth and 
metabolism in eukaryotes through mediation by two multi-protein complexes, mTORC1 
and mTORC2 (Saxton and Sabatini, 2017). mTORC1 is an intermediary of nutrient and 
energy sensing and maintains the balance between anabolism and catabolism in response 
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to environmental conditions. In the presence of pro-growth endocrine signals and 
sufficient energy, the mTORC1 pathway shifts toward increased anabolism and 
phosphorylates two substrates, p70 ribosomal S6 kinase 1 (S6K1) and eIF4E binding 
protein 1 (4E-BP1). Phosphorylation of S6K1 promotes protein synthesis and cell growth 
through multiple substrates, including translational regulator eIF4B, as well as eEF2K 
and ribosomal protein S6, both of which subsequently promote translation initiation and 
elongation (Mao and Zhang, 2018; Saxton and Sabatini, 2017; Ruvinsky et al., 2009). 
Multiple phosphorylations of 4E-BP1 by mTORC1 cause the protein to dissociate from 
eIF4E, allowing assembly of the eIF4F complex and mRNA translation to occur (Saxton 
and Sabatini, 2017; Yoon, 2017). A mTORC1-dependent shift towards anabolism can 
only occur when the appropriate endocrine signals and sufficient energy are present.  
 The main signaling pathways investigated in the current study begin with 
activation of insulin receptors (IR) and insulin-like growth factor type 1 receptors (IGF-
1R) on the surface of skeletal muscle cells by insulin and IGF-1. The functions of the IR 
and the IGF-1R appear to be physiologically distinct but overlapping, in that they can 
produce similar cellular responses. IR is a metabolic mediator and IGF-IR is primarily a 
growth promoter (Kim and Accili, 2002). In mice, observations have indicated that IGF-
1R can mediate glucose utilization in skeletal muscle (Di Cola et al., 1997); suggesting 
that IGF-1R works in tandem with IR for metabolic regulation in skeletal muscle. The 
main signaling pathways activated by IR and IGR-1R also overlap, in that they signal 
through PI3K/Akt and converge on the TSC1/TSC2 complex, culminating in mTOR 
mediated phosphorylation of S6K1 and 4E-BP1 (Saxton and Sabatini, 2017). IGF-1/IGF-
1R signaling to Akt/mTOR has been shown to be crucial in promoting muscle 
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hypertrophy, with muscle growth resulting from increased protein synthesis or decreased 
degradation in myofibers (Glass, 2005).  
 As previously mentioned, bromocriptine treated steers showed decreased insulin 
and glucose clearance, which indicated decreased insulin sensitivity. The primary action 
of insulin in skeletal muscle is to stimulate glucose uptake and metabolism, with 80% of 
total glucose uptake occurring in skeletal muscle (Abdul-Ghani and DeFronzo, 2010). 
This makes ergot alkaloid induced insulin sensitivity issues potentially detrimental to 
growing cattle in terms of overall health and energy metabolism. The primary defect that 
leads to insulin resistance in skeletal muscle is likely a defect in the insulin signaling 
cascade at insulin receptor substrate 1 (IRS-1), wherein the insulin receptor is 
downregulated by chronic hyperinsulinemia (Abdul-Ghani and DeFronzo, 2010). It is 
currently unknown if bromocriptine effects this receptor and there is very little research 
concerning alkaloid effects on the mTOR pathway, although structurally similar 
compounds (indoles) have been shown to inhibit PI3K/Akt/mTOR/NF-κB (Ahmad et al., 
2013). Lower insulin sensitivity in bromocriptine treated steers could impact IR signaling 
and downstream activation of pathway proteins. However, phosphorylation of mTOR at 
Ser2448 after glucose stimulation was higher in the presence of, suggesting some positive 
influence on the mTOR protein in bromocriptine treated steers. Yet this did not translate 
to an increase in downstream activation of S6K1 or 4E-BP1 proteins in either the basal or 
stimulated state, suggesting that bromocriptine did not have an inhibitory effect on 
activation of the mTOR pathway and consequently did not inhibit protein synthesis which 
is in agreement with the previous section, concerning protein turnover.  
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 Insulin in conjunction with increased signaling by IGF-1 in implanted steers, was 
expected to produce downstream activation of mTOR, resulting in phosphorylation of 
S6K1 and 4E-BP1, which in turn would promote protein synthesis. However, an increase 
in phosphorylation at Ser2448 was not seen for mTOR, nor were any significant changes 
to S6K1 in either the basal or stimulated state in implanted steers. There did appear to be 
a numerical increase in phosphorylation and activation status of S6K1 in the stimulated 
state in implanted steers. Surprisingly, activation status and phosphorylation of 4E-BP1 
were lower in implanted steers, indicating interference with skeletal muscle protein 
translation initiation in the presence and absence of bromocriptine. While the current 
study did not show any significant decreases in protein synthesis in implanted steers — 
despite interference at 4E-BP1 — Lobley et al. (1985) demonstrated that implant-treated 
steers showed a slight decline in synthesis. This suggests that hormonal implants decrease 
the rate of protein synthesis and as previously discussed, accomplish protein accretion 
instead through decreased protein turnover and degradation. These results partially 
contradict previous research in mice and rats showing that IGF-1 activation of mTOR 
stimulates protein synthesis and muscle hypertrophy through S6K1 and 4E-BP1 (Glass, 
2005). Numerically, S6K1 showed the anticipated increases in activation status, but 4E-
BP1 showed the opposite. This is not unexpected as it has been previously shown that 
while S6K1 and 4E-BP1 both possess the TOR signaling motif, which is essential for 
mTOR activation, mTOR exhibits differing kinase activity towards S6K1 and 4E-BP1 
(Figueiredo et al., 2017). The mTOR protein also has multiple residues that can undergo 
phosphorylation (Figueiredo et al., 2017). Perhaps in the current study phosphorylation 
occurred at a site other than Ser2448, which could explain any disparity between 
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activation of mTOR and phosphorylation of downstream proteins. In this case, because 
DMI was controlled, protein synthesis may have been stimulated through a pathway 
independent of mTOR, such as inhibition of GSK3β by Akt (Glass, 2005). It has also 
been demonstrated that the stimulatory effect of IGF-1 on cell proliferation is mediated 
through the MEK/ERK pathway (Coolican et al., 1997; Jones et al., 2001) and inhibition 
of protein degradation in myotubes is through the PI3K/Akt/FoxOsa pathway (Ge et al., 
2013). Since protein abundance of upstream regulators of mTOR and these independent 
pathways were not evaluated in the current study, further investigation is required to get 
an accurate representation of the effects of estradiol/TBA implants on protein metabolism 
in cattle. 
 To our knowledge the effect of long-term administration of bromocriptine on the 
mTORC1, S6K, and 4E-BP1 has not been previously studied in cattle. The current study 
indicated that bromocriptine influenced potential relationships between pre- and post-
glucose infusion levels of phosphorylated mTOR and total 4E-BP1. Bromocriptine 
treatment appeared to permit expression of a positive relationship between pre- and post- 
infusion abundance of phosphorylated mTOR. In other words, bromocriptine stimulation 
of post-infusion phosphorylated mTOR was only seen in cases with high pre-infusion 
concentrations of that phosphorylated protein. This suggests that bromocriptine may 
encourage activation of the mTOR protein at Ser2448. Conversely, bromocriptine 
appeared to nullify the positive relationship between pre- and post- infusion abundance of 
total 4E-BP1, suggesting that bromocriptine may have some effect on the expression of 
the 4E-BP1 protein. These findings demonstrate that long term administration of 
bromocriptine affected signal transmission between glucose, insulin, and the mTOR 
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pathway. At this time, the exact mechanism of action for this novel response is unknown 
and requires further investigation of upstream signaling to mTOR and mTOR 
independent pathways to elucidate what occurred in the current study. 
Conclusion 
 Injection with bromocriptine was successful in inducing a fescue toxicosis-like 
syndrome in steers, and treatment with a combined estradiol + TBA implant was able to 
improve the performance and ADG of cattle, even in the presence of fescue-derived 
alkaloids. Bromocriptine treatment caused reduced insulin and glucose clearance after an 
IVGTT, indicating decreased insulin sensitivity and possible disruption of glucose uptake 
and metabolism in the skeletal muscle. This suggests that ergot alkaloids are detrimental 
to growing cattle in terms of overall glucose homeostasis and energy metabolism. 
However, there were no detrimental effects of bromocriptine on protein synthesis or N 
retention. Implantation improved N retention, decreased protein turnover, and had no 
effect on protein synthesis, suggesting that steroidal implants promote protein accretion 
through unchanged rates of synthesis and decreased degradation, which may allow for 
more energy to be available for growth, even in the presence of bromocriptine. Although 
previous research suggested that combined estradiol + TBA treatment would increase 
IGF-1 signaling in implanted steers, activation of mTOR and stimulation of protein 
synthesis through downstream activation of S6K1 and 4E-BP1 does not appear to have 
transpired, and results suggest steroidal interference occurred at 4E-BP1. This is in 
agreement with Lobley et al. (1985) who demonstrated that implant-treated steers showed 
a slight decline in synthesis. This further supports the assertion that implantation 
accomplishes protein accretion through decreased protein turnover and degradation, even 
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in the presence of bromocriptine. Bromocriptine did not affect S6K1 or 4E-BP1, so does 
not appear to inhibit activation of the mTOR pathway or protein synthesis, which is in 
agreement with the results of the protein turnover analysis. This suggests that, when feed 
intake is controlled, the decreased performance in cattle exposed to fescue-derived 
alkaloids stems from issues with glucose homeostasis and skeletal muscle metabolism, 
disruption of upstream signals in the mTOR pathway, or disturbances in pathways 
independent of mTOR. These results also suggest that many of the differences in animal 
performance seen in cattle affected by fescue toxicosis may be attributed to differences in 
feed intake. 
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Table 3.1. Composition of experimental diet fed to steers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Supplement included soybean meal, ground corn, limestone, trace mineral premix, fat, 
vitamin premix, and Rumensin 90. Trace mineral premix provided 92.9% salt, 68 ppm 
Co, 1838 ppm Cu, 120 ppm I, 9290 ppm Mn, 19 ppm Se, and 5520 ppm Zn. Vitamin 
premix supplied 1820 IU/kg Vitamin A, 363 IU/kg Vitamin D, and 227 IU/kg Vitamin E.
Item Percentage (DM basis) 
Ingredient  
     Corn Silage 61.00 
     Cracked Corn 24.00 
     Supplement1 10.00 
     DDGS 5.00  
Analyzed chemical components  
     DM, % 49.00 
     Crude Protein, % 13.00 
     Ca, %  0.55 
     P, % 0.48 
Calculated energy densities   
     NEm, MCal/kg 0.81 
     NEg, MCal/kg 0.52 
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Table 3.2  Prolactin area under the curve, dry matter intake, body weight at enrollment, body weight change, and average 
daily gain in steers treated with bromocriptine and estradiol/TBA implants 
 
 + Bromo - Bromo  P-values 
 + Implant - Implant + Implant - Implant SEM1 Bromo Implant Bromo*Implant 
Prolactin AUC 1853 1754 3013 3543 492 0.002 0.61 0.45 
DM Intake, kg/day 6.18 6.14 6.24 6.20 0.08 0.22 0.44 0.99 
Starting weight, kg 330.9 329.9 334.3 335.1 5.6 0.29 0.99 0.82 
Weight change d1-8, kg 5.68 4.66 7.61 3.47 1.88 0.79 0.07 0.26 
Weight change d8-15, kg 6.31 1.50 7.05 5.51 1.19 0.04 0.01 0.15 
Weight change d15-22, kg 7.22 5.80 9.21 6.42 1.19 0.12 0.02 0.41 
Total gain, kg 19.21 13.58 23.87 15.40 2.04 0.01 <.0001 0.25 
ADG, kg 0.92 0.65 1.14 0.73 0.10 0.01 <.0001 0.25 
1SEM = standard error of the mean; +Bromo/+Implant (B+I) n = 8; +Bromo/-Implant (BROMO) n = 8, except for Weight change d8-
15 value where n = 7; -Bromo/+Implant (IMP) n = 8; and -Bromo/-Implant (CON) n = 8. 
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Table 3.3  Protein metabolism in steers treated with bromocriptine and estradiol/TBA implants 
 
  + Bromo - Bromo 
 
P-values 
  + Implant - Implant + Implant - Implant SEM1 Bromo Implant Bromo*Implant 
Urea excretion (g/day) 38.88 50.60 44.28 57.27 4.97 0.13 0.006 0.87 
15N Fractional Recovery 0.13 0.18 0.15 0.18 0.02 0.30 0.03 0.64 
Protein Turnover (g N/day) 132.3 136.7 131.1 147.1 8.6 0.43 0.10 0.32 
Protein Synthesis (g N/day) 112.4 113.0 109.4 118.6 7.5 0.85 0.47 0.52 
1SEM = standard error of the mean; +Bromo/+Implant (B+I) n = 5; +Bromo/-Implant (BROMO) n = 6; -Bromo/+Implant (IMP) n= 6; 
and -Bromo/-Implant (CON) n = 7.  
 
 
Table 3.4 Area under the curve and peak height of plasma glucose from steers treated with bromocriptine and estradiol 
implants before and following an IV glucose bolus 
 
 + Bromo - Bromo  P-values 
 + Implant - Implant + Implant - Implant SEM1 Bromo Implant Bromo*Implant 
AUC 17450 16860 16095 16318 781 0.09 0.73 0.45 
Peak Height (mg/dL) 219.5 231.0 228.2 223.0 8.8 0.97 0.70 0.32 
1SEM = standard error of the mean; n = 8. 
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Table 3.5  Area under the curve, peak height, and time to peak of plasma insulin from steers treated with bromocriptine and 
estradiol implants before and following an IV glucose bolus 
 
 + Bromo - Bromo P-values 
 + Implant - Implant + Implant - Implant Bromo Implant Bromo*Implant 
 Mean ± SE Mean ± SE Mean ± SE Mean ± SE    
AUC 11984 ± 1136 9005 ± 1136 7386 ± 1136 8718 ± 1136 0.04 0.47 0.07 
Peak Height (µIU/mL) 220.5 ± 26.2 167.8 ± 26.2 162.5 ± 26.2 211.3 ± 26.2 0.79 0.94 0.07 
Time to Peak (mins)1 16.25 ± 2.89 20.00 ± 0.95 15.00 ± 1.61 15.00 ± 0.97 0.09 0.29 0.29 
1Data analyzed with heterogenous variance model  
Data are presented as least squares means ± standard error of the mean; n = 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
Table 3.6  Relative abundance in arbitrary units of activated, phosphorylated, and total mTOR proteins in muscle of steers 
treated with bromocriptine and estradiol implants before (pre) and in response (post) to an IV glucose bolus 
 
  + Bromo - Bromo  P-values Covariate P-values 
  
+ Implant - Implant + Implant - Implant SEM1 Bromo Implant 
Bromo*
Implant Pre Pre*Bromo 
Pre Ratio 0.81 0.81 0.87 0.70 0.08 0.63 0.21 0.18 - - 
 Pho 0.81 1.07 0.84 0.64 0.18 0.19 0.83 0.12 - - 
 Total 0.97 1.23 0.90 0.79 0.13 0.05 0.55 0.14 - - 
            
Post Ratio 1.35 1.28 1.25 1.27 0.10 0.38 0.69 0.53 0.98 0.96 
 Pho 1.73 1.85 1.23 1.63 0.27 0.04 0.14 0.42 0.10 0.0012 
 Total 1.26 1.42 1.20 1.46 0.21 0.94 0.20 0.76 0.01 0.21 
Ratio data represent the ratio of phosphorylated to total protein (i.e. activation status). Pho data represent the abundance of 
phosphorylated form of each protein. Total data represent the relative abundance of the total form of each protein.  
1SEM = standard error of the mean; +Bromo/+Implant (B+I) n = 8; +Bromo/-Implant (BROMO) n = 8; -Bromo/+Implant (IMP) n = 8, 
except for Post-Pho values where n = 7; and -Bromo/-Implant (CON) n = 8, except for Pre-Ratio values where n = 7. 
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Table 3.7  Relative abundance in arbitrary units of activated, phosphorylated, and total S6K1 proteins in muscle of steers 
treated with bromocriptine and estradiol implants before (pre) and in response (post) to an IV glucose bolus 
 
  + Bromo - Bromo P-values Covariate P-values 
  + Implant - Implant + Implant - Implant Bromo Implant Bromo*Implant Pre Pre*Bromo 
  Mean ± SE Mean ± SE Mean ± SE Mean ± SE      
Pre Ratio 0.08 ± 0.01 0.05 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.82 0.24 0.12 - - 
 Pho1 0.10 ± 0.02 0.06 ± 0.01 0.10 ± 0.03 0.08 ± 0.02 0.63 0.12 0.63 - - 
 Total 1.32 ± 0.15 1.42 ± 0.15 1.34 ± 0.15 1.14 ± 0.15 0.20 0.60 0.15 - - 
           
Post Ratio1 1.54 ± 0.55 0.63 ± 0.12 0.90 ± 0.36 0.75 ± 0.13 0.46 0.14 0.28 0.66 0.22 
 Pho1 1.30 ± 0.54 0.53 ± 0.10 0.86 ± 0.37 0.67 ± 0.16 0.66 0.17 0.40 0.78 0.17 
 Total 0.76 ± 0.06 0.76 ± 0.07 0.83 ± 0.06 0.92 ± 0.07 0.05 0.40 0.41 <.0001 0.17 
1Data analyzed with heterogenous variance model  
Ratio data represent the ratio of phosphorylated to total protein (i.e. activation status). Pho data represent the abundance of 
phosphorylated form of each protein. Total data represent the relative abundance of the total form of each protein. Data are presented 
as least squares means ± standard error of the mean. +Bromo/+Implant (B+I) n = 8; +Bromo/-Implant (BROMO) n = 8, except for 
Post-Total values where n = 7; -Bromo/+Implant (IMP) n = 8, except for Pre-Ratio values where n = 7; and -Bromo/-Implant (CON) n 
= 8. 
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Table 3.8  Relative abundance in arbitrary units of activated, phosphorylated, and total 4E-BP1 proteins in muscle of steers 
treated with bromocriptine and estradiol implants before (pre) and in response (post) to an IV glucose bolus 
 
  + Bromo - Bromo  P-values Covariate P-values 
  + Implant - Implant + Implant - Implant SEM1 Bromo Implant Bromo*Implant Pre Pre*Bromo 
Pre Ratio 0.71 0.58 0.58 0.62 0.08 0.42 0.38 0.15 - - 
 Pho 0.97 0.87 0.83 0.76 0.14 0.30 0.47 0.91 - - 
 Total 1.32 1.47 1.45 1.17 0.12 0.44 0.57 0.06 - - 
            
Post Ratio 0.79 0.90 0.63 0.86 0.08 0.11 0.01 0.34 0.30 0.56 
 Pho 0.74 0.90 0.66 0.90 0.10 0.60 0.02 0.59 0.006 0.80 
 Total 0.99 1.01 0.96 1.15 0.09 0.005 0.04 0.10 <.0001 0.003 
Ratio data represent the ratio of phosphorylated to total protein (i.e. activation status). Pho data represent the abundance of 
phosphorylated form of each protein. Total data represent the relative abundance of the total form of each protein.  
1SEM = standard error of the mean; n=8. 
  
 
 100   
 
 
Figure 3.1  Mean plasma concentrations of prolactin (ng/mL)  
Values are means ± SE of plasma prolactin concentrations for steers treated with 
bromocriptine injections and estradiol/TBA implants from weekly samples over 29 days. 
Day 1 represents sample taken immediately before treatment administration. Days 
denoted with * show bromocriptine treatment significantly decreased prolactin (Day 8, P 
= 0.04; Day 15, P = 0.001). Days denoted with ** show bromocriptine treatment 
significantly decreased prolactin (P = 0.002), implantation significantly decreased 
prolactin (P = 0.02), and a bromo x implant interaction (P = 0.01). Data for each day 
analyzed as a randomized complete block, terms of the model included bromo, implant, 
and their interactions, in a 2x2 factorial structure.  
Control n = 6; Bromo n = 8; Implant n = 7; and Bromo+Implant n = 7. 
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Figure 3.2  Mean plasma concentration of glucose (mg/dL) 
Values are means ± SE of plasma glucose concentrations during intravenous glucose 
tolerance test (IVGTT) for steers treated with bromocriptine injections and estradiol/TBA 
implants performed on d 35. Used to determine area under the curve which tended to be 
higher with bromocriptine treatment (P = 0.09) and peak height. Time point 0 represents 
sample taken immediately before intravenous glucose bolus administration (0.25 g/kg 
BW). Area under the curve and peak height were analyzed as a randomized complete 
block, terms of the model included bromo, implant, and their interactions, in a 2x2 
factorial structure. 
n = 8 for all treatments. 
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Figure 3.3  Mean plasma concentration of insulin (µIU/mL) 
Values are means ± SE of plasma insulin concentrations during intravenous glucose 
tolerance test (IVGTT) for steers treated with bromocriptine injections and estradiol 
implants performed on d 35. Used to determine area under the curve, peak height, and 
time to peak. Bromocriptine significantly increased AUC (P = 0.04) and there was a trend 
(P = 0.09) for it to increase time to peak. There was a significant bromo x implant 
interaction (P = 0.07) which increased AUC and peak height. Time point 0 represents 
sample taken immediately before intravenous glucose bolus administration (0.25 g/kg 
BW). Area under the curve, peak height, and time to peak were analyzed as a randomized 
complete block, terms of the model included bromo, implant, and their interactions, in a 
2x2 factorial structure.           
n = 8 for all treatments. 
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Figure 3.4  Representative graph of the interaction between pre-infusion levels of 
phosphorylated mTOR and bromocriptine treatment on post-infusion levels of 
phosphorylated mTOR 
For covariate analysis, pre and its treatment interactions were first tested as fixed effects 
(pre, pre x bromo, pre x implant, and pre x bromo x implant) to determine which 
covariates were significant (P < 0.05). Insignificant covariates were dropped from the 
model. The pre x bromo interaction was significant (P = 0.0012), demonstrating that pre 
glucose infusion levels of phosphorylated mTOR affected the amount of phosphorylated 
mTOR found post infusion in animals treated with bromocriptine. There was a positive 
relationship between pre- and post- infusion abundance in bromocriptine treated steers. In 
the absence of bromocriptine, there was no relationship between pre- and post- infusion 
phosphorylated protein abundance. Each point represents an individual steer. 
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Figure 3.5  Representative graph of the interaction between pre-infusion levels of 
total 4E-BP1 and bromocriptine treatment on post-infusion levels of total 4E-BP1 
For covariate analysis, pre and its treatment interactions were first tested as fixed effects 
(pre, pre x bromo, pre x implant, and pre x bromo x implant) to determine which 
covariates were significant (P < 0.05). Insignificant covariates were dropped from the 
model. The pre x bromo interaction was significant (P = 0.003), demonstrating that pre 
glucose infusion levels of total 4E-BP1 affected the amount of total 4E-BP1 found post 
infusion in animals treated with bromocriptine. There was a positive relationship between 
pre- and post- infusion abundance in steers not treated with bromocriptine, but in the 
presence of bromocriptine, there was no relationship between pre- and post- infusion total 
protein abundance. Each point represents an individual steer. 
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CHAPTER 4. SUMMARY AND CONCLUSIONS 
 Tall fescue (Festuca arundinacea) is the most important pasture forage in the 
United States, occupying 12 to 14 million ha and supporting millions of livestock 
(Buckner et al., 1979). Its vitality can be attributed to a mutualistic relationship with the 
endophytic fungi Epichloё coenophiala, which extends the grass’ growing season, and 
enhances its adaptability and persistence under heavy grazing (Buckner et al., 1979). 
Soon after it rose to prominence, tall fescue gained a reputation for inducing performance 
issues in livestock. It was later discovered that the cause was the variety of toxic ergot 
alkaloids produced by the endophyte fungus. High levels of ergot alkaloids result in three 
syndromes: fescue foot, fat necrosis, and summer slump. Notable symptoms include, 
elevated respiration, failure to shed the winter haircoat, heat intolerance, reductions in 
weight gain and milk production, and in extreme cases, gangrene of the extremities 
(Hoveland, 2009). Fescue toxicosis impacts all species in the grazing industry and results 
in an estimated, combined annual loss of up to $1 billion per year (Strickland et al., 
2011). 
 Animal disorders associated with tall fescue are the result of ergot alkaloids 
liberated from the forage in the gastrointestinal tract. The diverse effects of alkaloids are 
directly related to the structural similarities between them and the biogenic amine 
neurotransmitters norepinephrine, dopamine, and serotonin; which regulate appetite, 
cardiovascular function, endocrine activity, gastrointestinal motility, muscle contraction, 
and thermo regulation (Berde and Strumer, 1978; Thompson and Stuedemann, 1993). 
This allows alkaloids to bind to multiple neurotransmitter receptors throughout the body 
and obstruct their normal performance. Interference with serotonin and adrenergic 
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receptors has been shown to cause vasoconstriction of bronchial, subcutaneous and 
peripheral blood vessels and is believed to be the cause of the respiratory and circulatory 
issues that are common in affected animals (Oliver, 1997; Dyer, 1993). Animals suffering 
from fescue toxicosis also experience a sharp reduction in serum prolactin, caused by 
activation of dopamine receptors by ergot alkaloids (Schillo et al., 1988). Prolactin is 
essential for regulating metabolism, the immune system, milk synthesis, milk secretion, 
and pancreatic development. Decreased livestock productivity may also result from 
disruption of normal function of dopaminergic and adrenergic receptors in the pancreas 
as well. The synthetic alkaloid bromocriptine has been shown to reduce serum 
triglycerides, inhibit insulin secretion, and decrease body weight in rats and humans 
(Kalra et al., 2011; Lopez Vicchi et. al., 2016).  
 Many attempts have been made to improve the performance of stocker cattle 
grazing endophyte infected fescue, and steroidal implants have been shown to increase 
ADG in affected cattle (Brazle and Coffey, 1991; Beconi et al., 1995; Aiken et al., 2006; 
Carter et al., 2010). Androgenic and estrogenic steroids have been used for decades to 
enhance feed efficiency, rate of gain, and muscle accretion in feedlot cattle. Cattle given 
implants containing estradiol and trenbolone acetate have an increased number of muscle 
satellite cells, increased expression of IGF-1 mRNA in muscle tissue, and increased 
levels of circulating IGF-1 (Dayton and White, 2014). Local production of IGF-1 in 
skeletal muscle is thought to play a role in supporting hypertrophy and increased muscle 
growth observed in anabolic steroid-treated animals (Kamanga-Sollo et al., 2008b). 
Despite improvements seen with implant treatment, it has also been demonstrated that 
cattle grazing endophyte-infected pastures not only had lower rates of gain compared to 
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cattle grazing non-infected fescue, but also exhibit a slight decrease in IGF-1 
responsiveness to estradiol-17β (Davenport et al. (1993). IGF-1 is an important stimulator 
of the mTOR pathway, which regulates protein synthesis and muscle gain in growing 
animals (Yoon, 2017). Ergot alkaloids and structurally similar chemicals (indoles) have 
been shown to inhibit the growth hormone axis (Flückiger et al., 1978) and the mTOR 
pathway (Ahmad et al., 2013), respectively, in other species, but research investigating 
the effects of ergot alkaloids on these metabolic pathways, particularly in cattle, is 
severely lacking.  
 The aims of this research were to determine if fescue-derived alkaloids decrease 
muscle protein synthesis though inhibition of the mTOR pathway by directly affecting 
signal proteins, and if these negative effects could be alleviated by implantation with 
anabolic agents. Fescue toxicosis was successfully induced using the synthetic alkaloid, 
bromocriptine, resulting in reduced circulating prolactin after one week of treatment. 
Treatment with a combined estradiol-17β and trenbolone acetate implant mitigated some 
of the adverse effects of bromocriptine, allowing steers to gain more weight throughout 
the treatment period. Bromocriptine reduced insulin and glucose clearance following an 
intravenous glucose tolerance test, indicating decreased insulin sensitivity which would 
result in disruption of glucose uptake and metabolism in the skeletal muscle. This 
suggests that fescue-derived alkaloids are detrimental to growing cattle in terms of 
overall glucose homeostasis and energy metabolism. Conversely, analysis of whole-body 
protein turnover demonstrated that bromocriptine does not appear to affect protein 
synthesis or N retention and western immunoblot analysis of skeletal muscle showed that 
it did not affect abundance of S6K1 or 4E-BP1, so does not appear to inhibit activation of 
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the mTOR pathway or protein synthesis. Implantation improved N retention, decreased 
protein turnover, and had no effect on protein synthesis, suggesting that steroidal 
implants promote protein accretion through unchanged rates of synthesis and decreased 
degradation, even in the presence of bromocriptine. Implanted steers may have 
experienced increased IGF-1 signaling, but downstream activation of mTOR, S6K and 
4E-BP1, and thus increased protein synthesis, did not occur. These results also suggest 
that steroidal implants interfere with phosphorylation and abundance of 4E-BP1, 
blocking mRNA translation.  
 Overall, this research suggests that the poor performance of cattle exposed to 
ergot alkaloids originates with perturbation of skeletal muscle metabolism, specifically 
disruption of upstream signals in the mTOR pathway, or in pathways independent of 
mTOR. These results also suggest that many of the performance losses in cattle grazing 
endophyte infected tall fescue may be attributed to differences in feed intake, likely due 
to the negative effects of alkaloids on appetite and gastrointestinal motility. Further 
research should focus on the effects of fescue-derived alkaloids and steroid implants on 
cellular pathways independent of mTORC1, such as the PI3K/Akt/FoxO pathway 
(regulates inhibition of protein degradation in myotubes) and MEK/ERK pathway 
(regulates cell proliferation). Additionally, those located upstream like AMPK (senses 
glucose depravation) and downstream such as ULK1 (initiates autophagy), could provide 
further insight. Other cellular pathways could prove important in understanding the 
mechanisms by which ergot alkaloids cause such costly growth restrictions and health 
problems in cattle. 
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APPENDIX  
A. 1 Antibody Validations for Western Blot Analysis 
 The antibodies used in the research chapters, total and Ser2448 mTOR, total and 
Thr389 p70 S6 Kinase, and total and Thr37/46 4E-BP1 were validated in our lab to 
determine cross-species reactivity of these proteins in bovine muscle tissue. 
A.1.a mTOR Antibody Validation 
 To measure the abundance of 289 kDa mTOR, aliquots of pooled muscle sample 
from four randomly selected steers used in Chapter 3 were loaded into a polyacrylamide 
gel (8%). Identical samples were loaded in duplicate with one empty well separating the 
sets of pooled samples. Two molecular markers were also loaded onto the gel, Spectra to 
follow separation during electrophoresis and Magic Mark to verify the molecular weight 
of the protein bands after chemiluminescence. After separation by electrophoresis, the 
proteins were transferred onto a PVDF membrane and stained with Fast Green stain to 
verify if the protein transfer was successful. More information about the electrophoresis, 
transfer and staining procedures can be found in Chapter 3. Before the stain was removed 
with destain, the empty lanes were cut so that four pieces of membrane had an identical 
set of samples loaded. These membranes were placed in separate containers, washed and 
blocked with 5% fat-free milk dissolved in TBST for 1 hour at room temperature. During 
this time, the primary antibody and antigen (blocking peptide, catalog #1230, Cell 
Signaling Technology, Danvers, MA) mixtures were prepared and incubated for 1 hour at 
room temperature, per the manufacturer’s suggestion to allow for antibody-antigen 
interaction. Rabbit monoclonal antibody specific to Ser2448 mTOR (catalog #5536, Cell 
Signaling Technology, Danvers, MA) was mixed as a 1:1000 dilution in 5% bovine 
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serum albumin dissolved in TBST and divided into four conical tubes. The first tube 
contained only primary antibody and was expected to bind to phosphorylated mTOR 
without impediment. Antigen was added to the next three tubes so that the first had a 1:5 
mTOR antibody to antigen ratio, the second was 1:0.5, and the third a 1:0.05 ratio. These 
mixtures were then poured onto the membranes and allowed to incubate at 4 °C under 
gentle rocking overnight. The following day, the mixtures were removed, the membranes 
were washed and then probed with secondary antibody (Cell Signaling Technology, 
Danvers, MA, 1:2000 dilution in 5% fat-free milk dissolved in TBST) which was 
incubated for 1 hour at room temperature under gentle rocking. Membranes were then 
developed using a chemiluminescent kit (Amersham ECL Plus western blotting detection 
reagent, GE Healthcare Bio-Sciences, Pittsburgh, PA) and visualized using a digital 
imager (Azure c600, Azure Biosystems, Dublin, CA). The following figure shows that all 
ratios of the antibody:antigen solutions prevented the phosphorylated mTOR antibody 
from binding to the mTOR protein in bovine externus abdominis muscle samples, thereby 
validating the use of this primary antibody in cattle. 
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Figure A.1.1  Example gel showing the location of the band for phosphorylated 
mTOR and its disappearance when incubated with the antigen 
Lanes contained: (1 & 2) pooled bovine obliquus externus abdominis muscle incubated 
with 1:5 antibody:antigen solution, (4&5) pooled bovine muscle incubated with 1:0.5 
antibody:antigen solution, (7&8) pooled bovine muscle incubated with 1:0.05 
antibody:antigen solution, (9&10) pooled bovine muscle incubated with typical antibody 
solution, and (11) molecular weight marker.   
 
Following image capture, these membranes were stripped and re-blocked with 5% 
fat-free milk dissolved in TBST as described in Chapter 3, and re-probed, this time with 
the antibody for total mTOR (catalog #2983, Cell Signaling Technology, Boston, MA). 
Procedures for antigen incubation were repeated as described with the phosphorylated 
form but this time an antigen specific to total mTOR (blocking peptide, catalog #1072, 
Cell Signaling Technology, Boston, MA) was used, then the membranes were developed 
and visualized. The following figure shows that all ratios of the antibody:antigen 
solutions prevented the total mTOR antibody from binding to bovine externus abdominis 
muscle samples, thereby validating the use of this primary antibody in cattle. 
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Figure A.1.2  Example gel showing the location of the band for total mTOR and its 
disappearance when incubated with the antigen 
Lanes contained: (1 & 2) pooled bovine obliquus externus abdominis muscle incubated 
with 1:5 antibody:antigen solution, (4&5) pooled bovine muscle incubated with 1:0.5 
antibody:antigen solution, (7&8) pooled bovine muscle incubated with 1:0.05 
antibody:antigen solution, (9&10) pooled bovine muscle incubated with typical antibody 
solution, and (11) molecular weight marker. 
 
A.1.b. p70-S6 Kinase Antibody Validation 
 To measure the abundance of 70 and 85 kDa p70-S6 Kinase, aliquots of pooled 
muscle sample from post glucose challenge steers (from blocks 6 and 7) used in Chapter 
3, were loaded into a polyacrylamide gel (8%). Identical samples were loaded in 
duplicate with one empty well separating the sets of pooled samples, except for the first 
four lanes which were loaded without the empty well separating them, due to space 
limitations on the gel. Two molecular markers were also loaded onto the gel, Spectra to 
follow separation during electrophoresis and Magic Mark to verify the molecular weight 
of the protein bands after chemiluminescence. After separation by electrophoresis, the 
proteins were transferred onto a PVDF membrane and stained with Fast Green stain to 
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verify if the protein transfer was successful. More information about the electrophoresis, 
transfer and staining procedures can be found in Chapter 3. Before the stain was removed 
with destain, the membrane was cut between the sets of duplicate so that five pieces of 
membrane had an identical set of samples loaded. These membranes were placed in 
separate containers, washed and blocked with 5% fat-free milk dissolved in TBST for 1 
hour at room temperature. During this time, the primary antibody and antigen (custom 
blocking peptide, catalog #1630, Cell Signaling Technology, Danvers, MA) mixtures 
were prepared and incubated for 1 hour at room temperature, per the manufacturers 
suggestion to allow for antibody-antigen interaction. Rabbit monoclonal antibody specific 
to Thr389 p70 S6 Kinase (catalog #9234, Cell Signaling Technology, Danvers, MA) was 
mixed as a 1:1000 dilution in 5% fat-free milk dissolved in TBST and divided into five 
conical tubes. The first tube contained only primary antibody and was expected to bind to 
phosphorylated p70-S6K without impediment. Antigen was added to the next four tubes 
so that the first had a 1:5 p70-S6K antibody to antigen ratio, the second a 1:0.5 ratio, the 
third a 1:0.05 ratio, and the fourth a 1:0.005 ratio. These mixtures were then poured onto 
the membranes and allowed to incubate at 4 °C under gentle rocking overnight. The 
following day, the mixtures were removed, the membranes were washed and then probed 
with secondary antibody (Cell Signaling Technology, 1:2000 dilution in 5% fat-free milk 
dissolved in TBST) which was incubated for 1 hour at room temperature under gentle 
rocking. Membranes were then developed using a chemiluminescent kit (Amersham ECL 
Plus western blotting detection reagent, GE Healthcare Bio-Sciences, Pittsburgh, PA) and 
visualized using a digital imager (Azure c600, Azure Biosystems, Dublin, CA). The 
following figure shows that all but the 1:0.005 ratio of the antibody:antigen solutions 
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prevented the phosphorylated p70-S6 Kinase antibody from binding to bovine externus 
abdominis muscle samples, thereby validating the use of this primary antibody in cattle. 
 
Figure A.1.3  Example gel showing the location of the band for phosphorylated p70 
S6K and its disappearance when incubated with the antigen 
Lanes contained: (1&2) pooled bovine obliquus externus abdominis muscle incubated 
with 1:0.005 antibody:antigen solution, (4&5) pooled bovine muscle incubated with 
1:0.05 antibody:antigen solution, (7&8) pooled bovine muscle incubated with 1:0.5 
antibody:antigen solution, (10&11) pooled bovine muscle incubated with 1:5 
antibody:antigen solution, (12&13) pooled bovine muscle incubated with typical 
antibody solution, and (14) molecular weight marker. 
 
 Following image capture, these membranes were stripped and re-blocked with 5% 
fat-free milk dissolved in TBST as described in Chapter 3, and re-probed, this time with 
the antibody for total p70-S6 Kinase (catalog #2708, Cell Signaling Technology, 
Danvers, MA). Procedures for antigen incubation were repeated as described with the 
phosphorylated form but this time an antigen specific to total p70-S6 Kinase (catalog 
#1205, Cell Signaling Technology, Danvers, MA) was used, as well as a different ratio of 
antibody to antigen. The first tube contained only primary antibody and was expected to 
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bind to total p70-S6K without impediment. Antigen was added to the next four tubes so 
that the first had a 1:2 antibody to antigen ratio, the second a 1:0.2 ratio, the third a 1:0.02 
ratio, and the fourth a 1:0.002 ratio. Following incubation with secondary antibody the 
membranes were developed and visualized. The following figure shows that all ratios of 
the antibody:antigen solutions prevented the total p70-S6 Kinase antibody from binding 
to bovine externus abdominis muscle samples, thereby validating the use of this primary 
antibody in cattle. 
 
Figure A.1.4  Example gel showing the location of the band for total p70 S6K and its 
disappearance when incubated with the antigen 
Lanes contained: (1&2) pooled bovine obliquus externus abdominis muscle incubated 
with 1:0.002 antibody:antigen solution, (4&5) pooled bovine muscle incubated with 
1:0.02 antibody:antigen solution, (7&8) pooled bovine muscle incubated with 1:0.2 
antibody:antigen solution, (10&11) pooled bovine muscle incubated with 1:2 
antibody:antigen solution, (12&13) pooled bovine muscle incubated with typical 
antibody solution, and (14) molecular weight marker. 
 
A.1.c. 4E-BP1 Antibody Validation 
 To measure the abundance of 15-20 kDa 4E-BP1, aliquots of pooled muscle 
sample from steers from block 4 used in Chapter 3, were loaded into a polyacrylamide 
gel (12%). Identical samples were loaded in duplicate with one empty well separating the 
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sets of pooled samples. Two molecular markers were also loaded onto the gel, Spectra to 
follow separation during electrophoresis and Magic Mark to verify the molecular weight 
of the protein bands after chemiluminescence. After separation by electrophoresis, the 
proteins were transferred onto a PVDF membrane and stained with Fast Green stain to 
verify if the protein transfer was successful. More information about the electrophoresis, 
transfer and staining procedures can be found in Chapter 3. Before the stain was removed 
with destain, the empty lanes were cut so that four pieces of membrane had an identical 
set of samples loaded. These membranes were placed in separate containers, washed and 
blocked with 5% fat-free milk dissolved in TBST for 1 hour at room temperature. During 
this time, the primary antibody and antigen (blocking peptide, catalog #1052, Cell 
Signaling Technology) mixtures were prepared and incubated for 1 hour at room 
temperature, per the manufacturers suggestion to allow for antibody-antigen interaction. 
Rabbit monoclonal antibody specific to Thr37/46 4E-BP1 (catalog #2855, Cell Signaling 
Technology, Danvers, MA) was mixed as a 1:1000 dilution in 5% fat-free milk dissolved 
in TBST and divided into four conical tubes. The first tube contained only primary 
antibody and was expected to bind to phosphorylated 4E-BP1 without impediment. 
Antigen was added to the next three tubes so that the first had a 1:5 4E-BP1 antibody to 
antigen ratio, the second was 1:0.5, and the third a 1:0.05 ratio. These mixtures were then 
poured onto the membranes and allowed to incubate at 4 °C under gentle rocking 
overnight. The following day, the mixtures were removed, the membranes were washed 
and then probed with secondary antibody (Cell Signaling Technology, 1:2000 dilution in 
5% fat-free milk dissolved in TBST) which was incubated for 1 hour at room temperature 
under gentle rocking. Membranes were then developed using a chemiluminescent kit 
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(Amersham ECL Plus western blotting detection reagent, GE Healthcare Bio-Sciences, 
Pittsburgh, PA) and visualized using a digital imager (Azure c600, Azure Biosystems, 
Dublin, CA). The following figure shows that all ratios of the antibody:antigen solutions 
prevented the phosphorylated 4E-BP1 antibody from binding to bovine externus 
abdominis muscle samples, thereby validating the use of this primary antibody in cattle. 
 
Figure A.1.5  Example gel showing the location of the band for phosphorylated 4E-
BP1 and its disappearance when incubated with the antigen 
Lanes contained: (1&2) pooled bovine obliquus externus abdominis muscle incubated 
with 1:0.05 antibody:antigen solution, (4&5) pooled bovine muscle incubated with 1:0.5 
antibody:antigen solution, (7&8) pooled bovine muscle incubated with 1:5 
antibody:antigen solution, (10&11) pooled bovine muscle incubated with typical 
antibody solution, and (13) molecular weight marker. 
 
Following image capture, these membranes were stripped and re-blocked with 5% 
fat-free milk solution as described in Chapter 3, and re-probed, this time with the 
antibody for total 4E-BP1 (catalog #9644, Cell Signaling Technology, Danvers, MA). 
Procedures for antigen incubation were repeated as described with the phosphorylated 
form but this time an antigen specific to total 4E-BP1 (catalog# 1053, Cell Signaling 
 
118 
 
Technology, Danvers, MA) was used, then the membranes were developed and 
visualized. The first tube contained only primary antibody and was expected to bind to 
total 4E-BP1 without impediment. Antigen was added to the next three tubes so that the 
first had a 1:5 antibody to antigen ratio, the second a 1:0.5 ratio, and the third a 1:0.05 
ratio. Following incubation with secondary antibody the membranes were developed and 
visualized. The following figure shows that all ratios of the antibody:antigen solutions 
prevented the total 4E-BP1 antibody from binding to bovine externus abdominis muscle 
samples, thereby validating the use of this primary antibody in cattle. 
 
Figure A.1.6  Example gel showing the location of the band for total 4E-BP1 and its 
disappearance when incubated with the antigen 
Lanes contained: (1&2) pooled bovine obliquus externus abdominis muscle incubated 
with 1:0.05 antibody:antigen solution, (4&5) pooled bovine muscle incubated with 1:0.5 
antibody:antigen solution, (7&8) pooled bovine muscle incubated with 1:5 
antibody:antigen solution, (10&11) pooled bovine muscle incubated with typical 
antibody solution, and (13) molecular weight marker. 
 
A.2. Normalization to Total Protein 
Normalization to total protein was used as a loading control to reduce variation 
due to concentration (Aldridge et al., 2008). Total protein stains have been shown to 
accurately correct loading errors and to have no limitation of dynamic range, in addition 
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to being completely reversible (Romero-Calvo et al., 2010). To achieve the total protein 
stain, PVDF membranes were washed in Fast Green FCF solution (0.2g fast green, 50% 
methanol, 10% glacial acetic acid). Fast Green is an anionic dye that binds to all protein 
present on the membrane; making it useful when evaluating transfer efficiency and 
quantifying total protein (Luo et al., 2006). After electrophoresis and protein transfer, 
membranes were incubated with Fast Green for approximately 2 min, then washed with 
destain buffer (50% methanol, 10% glacial acetic acid) until the background was white 
and only the protein bound stain was visible. Once this occurred, an image of the total 
protein stain was obtained using a digital imager (Azure c600, Azure Biosystems, Dublin, 
CA). The membranes were then washed until all remaining Fast Green stain was removed 
before blocking and immunodetection as described in Chapter 3. The image of the stain 
was later quantified using the AzureSpot Software (Azure Biosystems, Dublin, CA); 
where each individual lane (representing different muscle samples) was quantified, and 
the background was subtracted, to determine the total amount of protein in each lane. The 
sample lane values were then normalized to the total protein signal for the positive 
control that was loaded onto each gel (pooled bovine muscle sample). Subsequently, 
these normalized total protein values were then used to normalize the band densities 
obtained for each protein measured as described in Chapter 3.  
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Figure A.2.1  Representative image of the total protein stain 
Lanes 1-4 are bovine muscle samples obtained from one block of steers post glucose 
challenge, lane 6 represents the pooled sample of bovine muscle as the positive control, 
and lanes 8-11 are bovine muscle samples obtained from the same block of steers before 
the glucose challenge. Lane 13 contains Magic Mark (only visible after 
chemiluminescence) and lane 14 contains Spectra, both are molecular weight markers. 
Lanes 5, 7, and 12 are empty lanes.
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